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ABSTRACT 
 
Systemic lupus erythematosus is a potentially fatal autoimmune disease 
that predominantly affects women.  Genetic and environmental factors both 
contribute to disease development, but how environmental factors cause 
epigenetic changes leading to pathogenesis is unclear.  CD4+ T cell DNA 
demethylation results in overexpression of several immune-relevant methylation-
sensitive genes, leading to functional consequences in lupus. Multiple 
environmental factors affect the methylation cycle, including micronutrients and 
oxidation of cellular components.  This dissertation aims to address the 
relationship between micronutrients, redox changes, and the expression of 
methylation-sensitive T cell genes in lupus. 
The first objective of this dissertation assessed levels of 8 micronutrients 
that are involved in methylation, in the serum of lupus patients.  We found zinc, 
vitamin B6, and methionine to be decreased and homocysteine to be increased 
in our cohort of lupus patients compared to the normal population.  In the second 
objective, we investigated whether altered levels of the same 8 micronutrients 
could alter expression of methylation-sensitive T cell genes in vitro.  We did this 
by developing a custom media in which the transmethylation micronutrient levels 
were adjusted to physiologic levels.  Our findings suggest that micronutrient 
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levels alter the expression of methylation-sensitive T cell genes and may have 
implications in lupus. 
We then examined the relationship between micronutrients and 
peroxynitrite, a potent pro-oxidant, in the third objective.  By treating T cells with 
peroxynitrite and culturing them in media with altered concentrations of folate and 
methionine, we determined that oxidant and micronutrient effects are additive in 
promoting increased gene expression.  Finally, we compared the effects of 
altered methionine on CD4+ T cells from lupus patients and age- and gender- 
matched controls, in the fourth and final objective of this dissertation.  The results 
suggest that T cells from lupus patients may be more sensitive to micronutrient 
alterations potentially due to increased levels of pro-oxidants.   
Overall, these studies strongly suggest a potential role for micronutrient 
modulation of T cells in lupus and establish a link between redox status and 
micronutrient effects on methylation-sensitive gene expression.  These findings 
provide a basis for future research on therapeutic benefits of dietary modification 
in autoimmunity. 
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CHAPTER I: INTRODUCTION 
 
 
Systemic Lupus Erythematosus 
 
 Systemic lupus erythematosus (SLE) is a chronic relapsing autoimmune 
disease affecting several organs of the body.  The most common organs involved 
are the skin, joints, and kidney, though other organs such as the heart, lungs, 
and brain may also be affected.  Clinical manifestations of lupus include discoid 
rash and the classic malar rash across the nose and cheeks, as well as oral 
ulcers, arthritis, pericarditis, pleurisy, glomerulonephritis, neuropsychiatric 
involvement and hematologic manifestations. 
 Lupus affects women in their childbearing years 9 times more often than 
men [1].  The exact prevalence of the disease is unknown, but is estimated at 
14.6-100 per 100,000 [2, 3].  Currently, there is no cure for lupus.  Due to 
improvements in treatment over the last several decades, the morbidity and 
mortality of SLE has significantly decreased, with the 10-year survival now at 
about 70% [4].  However, chronic complications associated with prolonged 
immune dysregulation and pharmaceutical use are significant. 
 The exact etiology of SLE is unknown, however a genetic predisposition is 
necessary.  The concordance rate of lupus in familial lupus is 2% [5] and 25-40% 
[6] in identical twins.  Further evidence for genetic involvement comes from the 
higher incidence of lupus in women compared to men.  Estrogen is partially 
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responsible since women in their childbearing years have the highest incidence 
of lupus and estrogen supplementation is associated with lupus flares (SELENA 
trial).  However, the presence of 2X chromosomes also contributes to the higher 
incidence.  Women with Turner‟s syndrome (XO) have a lower risk of lupus, 
similar to that of men  while men with Klinefelter‟s syndrome (XXY) have an 
approximately 14-fold higher risk than normal men, and a lupus risk similar to 
women [7].  Genome wide association studies (GWAS) have recently identified 
single nucleotide polymorphisms (SNPs) associated with lupus in at least 51 
genes (see Table 1).  However, despite the association of several genes with 
lupus, the estimated heritability of the disease according to GWAS reports is only 
15% [8].  This, along with incomplete concordance in identical twins, indicates a 
role for environmental factors in disease development. 
 Environmental factors that have been associated with lupus include drugs, 
UV light, silica exposure and cigarette smoking, as well as infections [9-16].  
Increased  oxidative stress is common to these and may be a mechanism by 
which environment contributes to autoimmunity.   In the case of drugs, 
structurally unrelated drugs have been implicated in lupus suggesting that more 
than one mechanism may be involved [17].  It is unclear how environmental 
factors contribute to lupus in a genetically predisposed individual, but multiple 
mechanisms are likely involved.  To date, few studies have examined the role of 
diet in lupus, another environmental factor likely to impact the disease. 
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Pathogenesis 
Several immune abnormalities characterize SLE, including autoantibody 
production, B and T cell defects, aberrant cytokine release and persistent 
activation of the complement system, all of which ultimately lead to tissue 
damage.  The presence of autoantibodies precedes clinical symptoms of disease 
by an average of 2-3 years [18].  Cells that are undergoing apoptosis provide 
antigenic stimulation.  Antigen-presenting-cells (APCs) such as dendritic cells, 
monocytes/macrophages and B cells present autoantigens resulting in activation 
of effector T cells that help B cells produce autoantibodies.  Autoantibodies can 
aggregate with antigens to form immune complexes which can become trapped 
in basement membranes of the kidney.  Autoantibodies can also bind antigens in 
target tissues and activate complement.   
 While autoantibodies are key players in the onset of SLE, they are not 
sufficient; genes are also required.  Only a small subset of individuals with 
autoantibodies go on to develop lupus.  Complement activation as well as 
cytokine, chemokine, and proteolytic enzyme release, and oxidative damage are 
necessary for organ inflammation and damage to occur.  Complement is needed 
for the removal of pathogens, immune complexes, apoptotic cells and debris.  
Indeed, hereditary deficiencies of the complement proteins C1q and C4 are 
associated with the monogenic forms of SLE.  However, dysregulated persistent 
activation of the complement system by immune complexes in lupus results in 
chronic inflammation. 
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 B and T cell abnormalities are abundant and contribute to disease 
pathogenesis in SLE.  Certain subsets of B cells including memory B cells as well 
as activated B cells and plasma cells, are increased in SLE, and require lesser 
stimuli to be activated [19, 20].  Normally B cells go through several selection 
checkpoints to remove autoreactive B cells.  However these checkpoints are 
defective in SLE leading to survival of autoreactive B cell subsets [21].  B-cell 
activating factor (BAFF/BLyS), a cytokine involved in promoting proliferation and 
survival of B cells, is increased in SLE patients [22].  Several genetic 
polymorphisms that predispose to SLE include those that affect B cell receptor 
(BCR) signaling, such as  protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) (PTPN22) and BLK proto-oncogene, Src family tyrosine kinase (BLK) 
[23, 24] . 
 T cells also respond to stimulation with an exaggerated response in lupus 
[25].  Assembly of the signaling apparatus after T cell receptor (TCR) activation is 
abnormal in SLE CD4+ T cells.  This results in suppression of IL-2 production, a 
cytokine important in the development and survival of regulatory T cells (Tregs) 
that function to limit inflammatory responses, and increased IL-17 production, 
which promotes inflammation [26].  Other T cell defects include possible defects 
in CD8+ cytotoxic T cells, decreased mitogen-activated protein (MAP) kinase 
activity, and altered cell surface receptors [27].  Proper cell surface receptor 
function is essential to the immune system.  Epigenetic changes in T cells have 
also been implicated in SLE pathogenesis. 
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DNA Methylation 
The intersection of gene and environmental interactions lies in the field of 
epigenetics.  Epigenetics is defined as heritable changes in gene expression that 
occur without a change in DNA sequence.  Epigenetic modifications include 
histone modifications such as acetylation, deacetylation, methylation and 
phosphorylation, and DNA methylation. 
 DNA methylation refers to the postsynthetic modification of deoxycytosine 
(dC) bases where a methyl group is added to carbon 5 to form 
deoxymethylcytosine (dmC) [28].  A „methyl mark‟ is thus created on the DNA, 
resulting in a stable epigenetic modification.  Cytosines that are methylated are 
almost always found in cytosine-guanine (CG) pairs.  Most (approximately 70-
80%) CG pairs are methylated in the mammalian genome [29].  The exceptions 
occur in regions of DNA rich in CG pairs, referred to as CpG islands (cytosine 
and guanine nucleosides linked by a phosphate), which are found in or near 
promoters of active genes [30, 31].  Methylation of regulatory regions usually 
corresponds to transcriptionally silent DNA while transcriptionally active DNA is 
typically unmethylated.  DNA methylation results in a closed, transcriptionally 
inactive chromatin configuration.  This occurs when methylcytosine binding 
proteins such as MECP2, MBD1, and MBD2 bind to dmC and recruit chromatin 
inactivation complexes to the methylated sequences.  This promotes chromatin 
condensation into a compressed configuration which is inaccessible to 
transcription initiation complexes [32]. 
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 DNA methylation is mediated by a group of enzymes called the DNA 
methyltransferases (Dnmts).  The importance of DNA methylation is 
demonstrated by the fact that homozygous deletion of any one of the Dnmts is 
embryonic lethal in mice [33].  During development, DNA methylation patterns 
are established by the „de novo‟ methyltransferases DNA methyltransferase 3a 
and 3b (Dnmt3a and Dnmt3b).  This serves to suppress expression of genes that 
are unnecessary or potentially detrimental to the function of the mature cells.  
Following differentiation, methylation patterns are maintained by DNA 
methyltransferase I (Dnmt1) which replicates the methylation patterns during 
mitosis [34-37].  Dnmt1 is upregulated by extracellular signal-regulated kinases 
(ERK) and c-Jun N-terminal kinases (JNK) pathway signaling during mitosis [38].  
Dnmt1 maintains methylation by binding the replication fork, then recognizing 
methylated CG pairs on the parent strand and methylating the corresponding CG 
pair on the daughter strand.  During this process, Dnmt1 transfers a methyl group 
from S-adenosylmethionine (SAM) to the unmethylated cytosine, forming 5-
methylcytosine and S-adenosylhomocysteine (SAH).  The transmethylation 
forward velocity is directly proportional to SAM concentration and Dnmt1 activity, 
and inversely proportional to SAH concentration (Figure 1.1).  Environmental 
factors causing a decrease in SAM concentration or Dnmt activity, or an increase 
in SAH concentration will effectively decrease DNA methylation. 
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T cells in lupus 
 The first evidence of a role for DNA methylation in lupus came from 
studies done where normal, antigen specific CD4+ T cells treated with 5-
azacytidine (5azaC), a DNA methylation inhibitor, became autoreactive, losing 
restriction for nominal antigen (Ag) and responding to self class II MHC 
molecules presenting inappropriate antigens [39].  5azaC is a nucleoside analog 
developed 50 years ago [40] which incorporates into DNA causing rapid passive 
loss of DNA methylation when Dnmt1 becomes covalently bound to 5-
azacytosine residues in the DNA [41].  CD4+ T cells treated with 5azaC also 
induced autologous B cell differentiation in the absence of exogenous antigen 
[42].  Further, adoptive transfer of murine CD4+ T cells treated with DNA 
methylation inhibitors into syngeneic hosts caused a lupus-like disease [43].  The 
autoreactivity was subsequently attributed in part to overexpression of 
lymphocyte function-associated antigen 1 (LFA-1; CD11a/CD18) on the 
demethylated cells [44], due to demethylation of the CD11a promoter [45].  LFA-
1 is an adhesion molecule that binds to intercellular adhesion molecule-1 (ICAM-
1) on APCs to stabilize T cell receptor-Ag binding to form the “immunologic 
synapse” resulting in T cell activation [46].  LFA-1 also acts as a costimulatory 
molecule for T cell activation [47].  Overexpression of LFA-1 contributes to T cell 
responsiveness in the absence of antigen in the binding cleft likely due to 
overstabilization of the T cell receptor-MHC interaction and/or increased 
costimulatory signals [48]. 
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 The fact that 5azaC induced autoreactivity suggested that other 
environmental agents may induce autoreactivity through similar epigenetic 
mechanisms.  Interestingly, procainamide (Pca) and hydralazine (Hyd), two 
drugs strongly associated with lupus [17], were found to be DNA methylation 
inhibitors.  Procainamide is an antiarrhythmic drug and hydralazine an 
antihypertensive drug.  Treating human CD4+ T cells with procainamide, 
hydralazine, or 5azaC resulted in a decrease of total T cell genomic dmC content, 
as measured by reverse-phase HPLC [49], demonstrating that both 
procainamide and hydralazine are DNA methylation inhibitors.  Subsequently, 
human or murine CD4+ T cells treated with Pca or Hyd overexpressed LFA-1 
and became autoreactive  , and adoptive transfer of the autoreactive murine cells 
into syngeneic recipients caused a lupus-like disease identical to 5azaC treated 
T cells [50].  The observation that these drugs have distinct chemical structures 
suggests that multiple mechanisms may be involved in inducing autoimmunity 
[17].  Procainamide reversibly inhibits Dnmt1 enzymatic activity and hydralazine 
prevents Dnmt1 upregulation by inhibiting ERK pathway signaling through PKCδ 
[17].  These studies suggest that other environmental agents may be involved in 
triggering lupus through similar mechanisms. 
 A hallmark of lupus is increased antibody production.  T cells made 
autoreactive by DNA methylation inhibitors recognize self class II MHC 
molecules on B cells and overstimulate antibody production [51].  The 
experimentally demethylated cells also induce macrophage apoptosis by 
responding to self class II MHC molecules on macrophages.    The resultant 
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release of apoptotic material is highly antigenic and since macrophages normally 
remove apoptotic material, apoptotic debris accumulates.  Decreased clearance 
of apoptotic material or inducing macrophage apoptosis with clodronate vesicles 
in mice [52, 53] resulted in production of autoantibodies to nuclear antigens, thus 
the macrophage apoptosis likely stimulates autoantibody formation. 
 In lupus patients, T cell DNA methylation levels were decreased compared 
to controls, and patients with active lupus had lower total methylcytosine content 
compared to patients with inactive lupus [42].  Dnmt1 levels were decreased in 
lupus patients due to decreased ERK pathway signaling [54] caused by defective 
PKCδ phosphorylation [55].  Importantly, the defect in PKCδ activation was 
subsequently attributed to oxidative stress [56]. 
 As mentioned above, LFA-1 was overexpressed in T cells treated with 
DNA methylation inhibitors.  Patients with active lupus also overexpress LFA-1 
on a CD4+ T cell subset [44, 57].  The overexpression was due to demethylation 
of CD11a regulatory regions, identical to those demethylated in 5azaC-treated T 
cells [45].  Later studies found several other immune genes to be demethylated 
and overexpressed in CD4+ T cells treated with DNA methylation inhibitors and 
in CD4+ T cells from lupus patients.  These include CD70, perforin and the KIR 
genes [51, 58-60].  CD70 is a B cell costimulatory molecule that stimulates 
antibody production.  The overexpression of CD70 on experimentally 
demethylated cells and lupus T cells caused B cell overstimulation and antibody 
production that was abrogated by anti-CD70 [51].  The perforin and KIR genes 
are noteworthy since they are not normally expressed on CD4+ T cells, but 
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aberrantly expressed when demethylated as in the case of 5azaC-treated CD4+ 
T cells or lupus CD4+ T cells.  The KIR genes are normally expressed on natural 
killer (NK) cells and either stimulate or suppress various effector functions 
depending on the cytoplasmic domain [61].  KIR expression on demethylated 
CD4+ T cells and lupus T cells resulted in IFN-γ overexpression and macrophage 
killing [62].  IFN-γ stimulates antibody production [63] and as noted above, 
macrophage killing leads to autoantibody formation.  Perforin is a pore-forming 
cytotoxic molecule also expressed in NK cells and aberrantly expressed in 
demethylated and lupus CD4+ T cells.  Perforin lyses target cells by disrupting 
their cytoplasmic membranes [64] and promotes autoreactive macrophage killing 
by lupus CD4+ T cells [65], which can be inhibited by concanamycin A, a perforin 
inhibitor [66].  The functional consequences of these aberrantly expressed 
methylation-sensitive genes may contribute to the autoimmunity and 
pathogenesis seen in lupus through effects such as antibody production and 
macrophage killing. 
 
Micronutrients and DNA Methylation 
Several micronutrients and metabolites are involved in the 
transmethylation cycle (Figure 1.2).  SAM serves as the universal methyl donor 
for a number of methyl acceptors including DNA, RNA and protein [67].  SAH is 
the by-product of methylation and strongly inhibits the transmethylation reaction 
by binding the catalytic domain of SAM-dependent methyltransferases [68].  The 
SAM/SAH ratio is reflective of the flow of methyl groups from SAM to methyl 
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acceptors [69], with a decrease in the ratio indicative of lower methylation 
capacity [70].  Transmethylation micronutrients and their complex interactions 
affect DNA methylation by potentially mediating the SAM/SAH ratio.  Some of the 
key micronutrients/metabolites are outlined below. 
 
Methionine 
 Methionine is an essential amino acid that cannot be synthesized de novo 
in humans.  Methionine combines with ATP to form SAM by the enzyme 
methionine adenosyltransferase (MAT), and is therefore critical for maintaining 
the methylation cycle.  The importance of methionine in the methylation cycle is 
demonstrated by MAT1A knockout mice.  Methionine levels are increased 7-fold 
in MAT1A knockout mice and SAM is severely reduced by 74%, as might be 
expected from the inability to produce SAM.  The reactions to produce reduced 
glutathione (GSH) from methionine are reversible and it has been argued that 
GSH depletion leads to DNA hypomethylation by drawing methionine away from 
the methylation cycle [71].   However in the MAT1A knockout mice, GSH is 
surprisingly reduced, considering the presence of excess methionine.  This 
suggests that GSH is redirected towards the SAM cycle as a methionine source 
to drive methylation in the absence of MAT1A [72], highlighting the necessity for 
methionine in the methylation cycle. 
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Homocysteine 
 Homocysteine is not a dietary micronutrient, but an important metabolite in 
the methylation cycle.  Following DNA methylation by SAM, SAH can be 
hydrolyzed to homocysteine and adenosine.  In this reversible reaction, SAH 
synthesis is strongly favored over hydrolysis.  Therefore, efficient homocysteine 
removal prevents SAH accumulation which inhibits Dnmt1.  Homocysteine can 
be remethylated to form methionine or catabolized to sulfate and pyruvate.  
Plasma homocysteine is a very sensitive biomarker of folate adequacy [73] in 
deficient but also normal and above-normal levels of red blood cell folate [74].  
Elevations in plasma homocysteine have been associated with cardiovascular 
disease [75, 76] and stroke [77].  The increased risk is present at modest 
homocysteine elevations at greater than 11μmol/l [75] which is within the 
generally accepted normal range of 5-15μmol/l [78].  Interestingly, homocysteine 
levels are elevated in lupus patients [79], and SAH and homocysteine 
accumulation causes lymphocyte DNA demethylation [70]. 
 
Folate 
 Folate is a water-soluble B vitamin (vitamin B9) that is essential to the 
DNA biosynthesis and methylation cycles.  During insufficient times of dietary 
intake of folate or its synthetic form folic acid, DNA biosynthesis and methylation 
decreases.  A decrease in DNA biosynthesis results in reduced cell division 
causing anemia, leukopenia, and thrombocytopenia.  A decrease in the 
methylation cycle is observed by an elevation in plasma homocysteine [73].  The 
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primary form of folate to enter the bloodstream from intestinal cells is 5-
methylTHF [73].  In the methylation cycle, 5-methylTHF transfers a methyl group 
to homocysteine catalyzed by methionine synthase to synthesize methionine [80, 
81], and subsequently SAM.  Folate modulates DNA methylation through its 
effects on SAM [82].  Low folate status that is still considered clinically normal 
has been associated with increased risk of colorectal cancer [83, 84].  This is 
further supported by the observation that genetic polymorphisms such as 
MTHFR C677T that affect the folate pathway, modify colorectal cancer risk [85-
87].  DNA methylation in lymphocytes may be affected by another polymorphism 
in the same gene, MTHFR A1298C [88, 89].  Furthermore, a polymorphic variant 
of the gene encoding methionine synthase, MTR 2756A>G, has been associated 
with an increased risk of SLE in the Polish population [90].  It is clear from 
numerous studies that folate modulates DNA methylation, however the degree to 
which this occurs and direction of the change is still unclear.  
 
Choline 
 Choline is critical for membrane structural integrity, lipid and cholesterol 
metabolism, and is a precursor for the neurotransmitter acetylcholine.  Choline is 
also important in transmethylation pathways.  It is unclear whether normal dietary 
intake meets the nutrient needs for most people [91].  The US Institute of 
Medicine‟s Food and Nutrition Board established intake recommendations for 
choline for the first time in 1998 [92].  Choline is a major dietary source of methyl 
groups, though endogenous choline is present in the body from the de novo 
 14 
 
biosynthesis of phosphatidylcholine catalyzed by phosphatidylethanolamine N-
methyltransferase (PEMT) in the liver.  PEMT utilizes SAM as a methyl donor to 
form a new choline moiety, subsequently producing homocysteine [93].  
Interestingly, estrogen upregulates PEMT, thereby affecting endogenous choline 
synthesis [94] and consequently resistance to choline deficiency: premenopausal 
women fed a choline-deficient diet were more resistant to developing organ 
dysfunction compared to males and postmenopausal women [95].  In the 
transmethylation cycle, choline is important for one of the two parallel pathways 
by which homocysteine is remethylated to form methionine [96] thus lowering 
homocysteine concentrations [97].  The first pathway involves folate and vitamin 
B12 (see section on folate).  The second pathway utilizes betaine, a metabolite of 
choline, as the methyl group donor for the conversion of homocysteine to 
methionine.  Oral betaine supplementation has been shown to lower plasma 
homocysteine concentrations [98, 99].  Individuals with choline deficiency have 
elevated homocysteine levels and a decreased capacity to methylate 
homocysteine after a methionine load [100].  Additionally, dietary choline 
deficiency causes hypomethylation of DNA [101, 102] by decreasing SAM 
concentrations in tissues [103, 104].  Given the elevated homocysteine levels [79] 
and hypomethylation of T cell DNA [105] in SLE, choline may have implications 
in disease pathogenesis. 
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Vitamin B12 
 Vitamin B12, also known as cobalamin, is used by two enzymes: 
methylmalonyl coenzyme (CoA) mutase and methionine synthase.  
Methylmalonyl coenzyme (CoA) mutase functions in the citric acid cycle to 
metabolize amino acids and is compromised during vitamin B12 deficiency [73], 
however it only appears to have a critical function during embryonic life and in 
children, but not in adults.  Methionine synthase, on the other hand, is vital to the 
methylation cycle.  Vitamin B12 is utilized by methionine synthase to convert 
homocysteine to methionine.  In this process, 5-methyltetrahydrofolate (5-
methylTHF) is converted to tetrahydrofolate.  Any interruption in the vitamin B12-
dependent methionine synthase results in accumulation of homocysteine and 
decrease in SAM, thereby affecting methylation.  This is seen in the neuropathy 
that occurs with vitamin B12 deficiency, characterized by demyelination of the 
peripheral nerves and spinal column [106, 107].  Additionally, folate becomes 
„trapped‟ as 5-methylTHF and cannot be reversed to its precursor, therefore 
affecting DNA biosynthesis and cell division.  This is seen in the anemia that 
presents with vitamin B12 deficiency [73].  Vitamin B12 enters the human food 
chain from foods of animal origin.  Absorption of vitamin B12 is dependent on the 
production of intrinsic factor and hydrochloric acid by the parietal cells of the 
stomach.  The production of intrinsic factor and hydrochloric acid may be 
compromised in elderly populations in the fairly rare form of pernicious anemia 
[108] or more common atrophic gastritis [109], respectively.  The methylation 
disturbances caused by vitamin B12 deficiency may have implications for other 
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diseases in this population, particularly autoimmune diseases and cancer which 
both increase with age and are affected by methylation [110].  
 
Zinc 
 Zinc affects several aspects of the immune system.  These effects are 
numerous and include susceptibility to infection [111-120], fetal immunologic 
development [121-123], and effects on immunosuppressive conditions [124-128].  
Zinc also affects specific cells of the immune system including T and B 
lymphocytes.  Lymphocytes, particularly T lymphocytes, are reduced in number 
in the blood and peripheral lymphoid organs of zinc-deficient children with 
acrodermatitis enteropathica and patients receiving total parenteral nutrition [129, 
130]. 
 Zinc may also affect methylation.  The first study examining the 
relationship between zinc and methylation patterns was conducted in 1985.  Rats 
that were fed a zinc deficient diet had reduced utilization of methyl groups from 
SAM and this resulted in DNA and histone hypomethylation [131, 132].  Zinc 
affects two enzymes in the methylation pathway: betaine-homocysteine-S-
methyltransferase (BHMT) and methionine synthase.  BHMT is a zinc 
metalloenzyme that synthesizes methionine by catalyzing the transfer of methyl 
groups from betaine to homocysteine [133].  Methionine synthase utilizes zinc for 
active site conformational changes needed to catalyze the transfer of a methyl 
group to homocysteine to produce methionine [134, 135].  Both of these 
pathways are essential for remethylating homocysteine to form methionine and 
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subsequently the SAM needed for methylation, therefore depletion of zinc may 
lead to impaired enzyme activity and consequently hypomethylation. 
 
Vitamin B6 
 Though overt B-vitamin deficiencies have decreased, there is some 
evidence of widespread subclinical deficiency, particularly pyridoxine and 
riboflavin [73].  Subclinical deficiencies are not as obvious in their manifestations, 
but can have detrimental metabolic effects.  Vitamin B6, also known as 
pyridoxine, is important in the synthesis of enzymes of amino acid metabolism.  
Deficiency of vitamin B6 has been associated with immune system impairment 
[73].  Circulating lymphocytes are decreased and anemia may be present as well 
[136].  In the methylation cycle, vitamin B6 functions in the conversion of 
homocysteine to cystathionine, a precursor of GSH.  A decrease in vitamin B6 
results in elevated homocysteine levels.  The best biochemical marker of vitamin 
B6 deficiency is decreased plasma levels of the coenzyme pyridoxal 5‟-
phosphate (PLP) [73].  Plasma PLP levels decrease with age, therefore separate 
guidelines for adequate intake of vitamin B6 have been established for the 
elderly population [137]. 
 
Riboflavin 
 Riboflavin, also known as vitamin B2, participates in numerous oxidation-
reduction reactions by conversion to coenzymes flavin mononucleotide (FMN) 
and to flavin adenine dinucleotide (FAD).  These coenzymes function in 
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metabolic pathways and energy production through the respiratory chain [138, 
139].  Riboflavin deficiency occurs through inadequate dietary intake or through 
malabsorption in certain conditions such as lactose intolerance and celiac 
disease.  Riboflavin is necessary for the production of the coenzyme PLP (see 
section on vitamin B6), therefore riboflavin deficiency often occurs with vitamin 
B6 deficiency [140] and can affect the methylation cycle through interactions with 
vitamin B6. 
 
Oxidative stress and DNA methylation in lupus 
 Oxidative stress is traditionally defined as an imbalance between pro-
oxidants and antioxidants [141] and more recently to include a disruption of redox 
signaling and control and/or molecular damage [142] .  Oxidative stress has been 
associated with aging [143] and several pathological conditions including 
cardiovascular disease [144], diabetes [145], pulmonary diseases [146], 
neurodegenerative diseases [147], and cancer [148] .  Significant evidence 
indicates that oxidative stress may also contribute to SLE. 
 Lupus is characterized by chronic inflammation and a prooxidative state 
[149, 150].  Several markers of oxidative stress are increased in lupus patients.  
Urinary F2 isoprostane has been associated with patient-reported symptoms in 
SLE, suggesting that oxidative stress may contribute to the debilitating symptoms 
associated with the disease [150].  Multiple markers of protein oxidation are 
associated with lupus.  Protein carbonyls and 3-nitrotyrosine levels were 
increased in sera from SLE patients and correlated with disease activity [149, 
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151].  Furthermore, protein carbonyl levels were increased in patients with 
arthritis or arthralgia, cardiac involvement, or renal disease compared to those 
without, suggestive of a role for protein oxidation in organ damage [152]. 
 Reactive nitrogen species (RNS) have been implicated in lupus 
pathogenesis.  Nitric oxide (NO), in particular, has several immunoregulatory 
functions including regulation of T lymphocytes.  NO affects T cell function by 
mediating mitochondrial hyperpolarization following T cell activation [153].  
Additionally, T cell receptor signaling to antigen at the immunological synapse is 
selectively potentiated by NO derived from endothelial nitric oxide synthase 
(eNOS) [154].  The CD4+ T cell proliferation and differentiation into T helper 1 
(Th1) and Th2 cells that occurs following activation is influenced by NO whereby 
NO preferentially enhances Th1 cell differentiation [155, 156].  In SLE, NO 
production is increased.  One study measuring serum nitrite and nitrate levels 
found an increase in lupus patients that correlated with disease activity and 
damage [157].  Several studies demonstrate a role for NO in SLE T cell 
dysregulation [158-160].  Lupus T cells have permanently high mitochondrial 
membrane potential [161, 162].  Interestingly, lupus and normal T cells generate 
similar amounts of NO, however monocytes from lupus patients produce higher 
levels of NO compared to normal monocytes.  Since NO is a diffusible gas, the 
NO produced by monocytes may be affecting neighboring T cells.  NO produced 
by monocytes in SLE has been shown to contribute to T lymphocyte 
mitochondrial dysfunction [163].  Other NO-induced T cell effects in SLE include 
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increased mTOR activity [164] and TCR-induced rapid and sustained Ca2+ 
signal [163], and decreased TCRδ expression [165] and ATP level [166]. 
 NO is produced by the enzyme inducible nitric oxide synthase (iNOS) and 
can combine with superoxide anion (O2
˙ˉ) to generate the highly reactive 
metabolite, peroxynitrite (ONOO-).  ONOO- can modify proteins in several ways 
including oxidation and nitration.  Nitration of tyrosine residues by ONOO- results 
in the formation of 3-nitrotyrosine (3NT), a stable by-product of peroxynitrite 
formation [151, 167] .  While other measures of NO synthesis can be falsely 
elevated by medications and dietary nitrates, 3NT is a reliable marker of NO 
production that is unaffected by exogenous sources [167].  Importantly, 3NT 
levels are increased in lupus patients, and the increase correlated with disease 
activity [167].  Furthermore, 3NT was increased in patients with lupus nephritis 
compared to those without renal disease [167].  These findings suggest a role for 
nitrated proteins in the pathogenesis of SLE.  Recently, nitration of proteins has 
been implicated in epigenetic mechanisms of lupus pathogenesis. 
 As discussed above, DNA methylation is mediated by DNA 
methyltransferases.  The Ras-MAPK signaling pathway regulates Dnmt1 levels 
by activating the transcription factors activating protein 1 (AP-1).  DNA 
methylation was inhibited in actively proliferating cells by inhibiting this signaling 
pathway [168, 169].  Furthermore, human T cell Dnmt levels were decreased 
when RAS-MAPK pathway signaling was inhibited [170].  SLE patients have an 
impaired T cell extracellular signal-regulated kinase (ERK) 1/2 phosphorylation 
that is proportional to disease activity [54].  CD4+ T cells become autoreactive 
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when treated with DNA methylation inhibitors [171] and MEK inhibitors, which are 
ERK signaling pathway inhibitors [172].  An inducible transgenic mouse model 
that expresses a dominant negative MEK in T cells had decreases in T cell ERK 
pathway signaling when the transgene was turned on.  Additionally, the mice 
developed anti-ds-DNA antibodies and an “interferon signature” characteristic of 
autoimmunity [173].  Purified CD4+ T cells from patients also have an impaired 
ERK pathway [42].  These observations together suggest that aberrant ERK 
pathway signaling may decrease T cell DNA methylation and contribute to lupus. 
 Subsequent studies have shown that the defect in ERK pathway signaling 
is due to impaired PKCδ phosphorylation.  T cells from lupus patients with active 
disease and T cells treated with hydralazine, and ERK pathway inhibitor, were 
stimulated with phorbol myristate acetate (PMA), a molecule that induces 
activation of the ERK pathway by directly activating protein kinase C (PKC).  The 
PKCδ isoform but not PKCα or PKCθ showed impaired phosphorylation in 
response to stimulation.  Furthermore, human CD4+ T cells treated with Rottlerin, 
a selective PKCδ inhibitor, had similar decreases in ERK phosphorylation and 
overexpression of CD70 with demethylation of the TNFSF7 (CD70) promoter as 
lupus and hydralazine-treated T cells.  CD4+ T cells transfected with a dominant 
negative PKCδ also showed the same results [55].  Mice lacking PKCδ develop a 
lupus-like disease [174], supporting the hypothesis that defective PKCδ 
phosphorylation may contribute to lupus through impaired ERK pathway 
signaling and subsequent T cell DNA demethylation.  
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 The defect in PKCδ phosphorylation has recently been attributed to 
oxidative stress, specifically the nitration of PKCδ [56].  Treating CD4+ T cells 
from healthy subjects with increasing concentrations of ONOO- and stimulating 
with PMA resulted in PKCδ nitration.  This altered the phosphorylation pattern by 
decreasing threonine (T505) phosphorylation and increasing tyrosine (Y311) 
phosphorylation.  The PKCδ nitration induced by ONOO- also correlated with 
PMA-stimulated ERK phosphorylation, and since PKCδ T505 phosphorylation is 
upstream of ERK, this suggests a role for PKCδ nitration in the impaired ERK 
pathway signaling [55, 56].  Additionally, the study found increased amounts of 
nitrated PKCδ in T cells of patients with active lupus compared to controls.  
Oxidative stress may be contributing to SLE by altering signaling through the 
effects of ONOO- on PKCδ.  This in turn may affect Dnmt1 regulation and 
subsequently methylation-sensitive autoimmune-relevant gene expression. 
 
Summary 
 SLE is a multi-factorial disease in which genetic and environmental factors 
play a role.  Epigenetic changes, particularly DNA methylation in T cells, 
contribute to disease pathogenesis and may in part account for the 
environmental impact on the disease.  Which environmental factors and how they 
trigger disease in genetically predisposed individuals is unclear.  Micronutrients 
from diet impact the transmethylation reaction, and may play a part.  Additionally, 
oxidative stress is increased in lupus patients, affects DNA methylation, and is 
common to several environmental triggers associated with lupus. 
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We hypothesize that micronutrients affect methylation-sensitive gene expression 
in SLE and interact with oxidant effects to further promote aberrant gene 
expression.  This is examined in the following four specific aims: 
I. To determine if transmethylation micronutrient levels are decreased in 
lupus patients. 
II. To examine whether altered micronutrient levels affect methylation-
sensitive T cell gene expression. 
III. To investigate the interaction between oxidants and altered 
micronutrient levels on methylation-sensitive T cell gene expression. 
IV. To compare methylation-sensitive gene expression in lupus versus 
control T cells exposed to altered micronutrients. 
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V= 
k[Dnmt1][SAM] 
[SAH] 
Figure 1.1: Transmethylation reaction forward velocity. 
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CHAPTER II: TRANSMETHYLATION MICRONUTRIENT LEVELS IN LUPUS 
PATIENTS 
 
Introduction 
 SLE is a chronic relapsing autoimmune disease characterized by multiple 
immune abnormalities that lead to multi-system involvement and organ damage.  
Genetic and environmental factors play a role in disease development and age 
may also contribute.  Epigenetic changes in T cells, specifically DNA methylation, 
have been implicated as a mechanism by which environment may promote 
disease progression. 
 DNA methylation is a post-synthetic modification where a methyl group is 
transferred from SAM to cytosine nucleotides in the DNA by the Dnmt enzymes.  
DNA methylation is dependent on the enzymatic activity of Dnmt and the 
availability of SAM which is generated through the methylation cycle.  Multiple 
metabolites affect the methylation cycle including several micronutrients from diet.  
After transferring a methyl group from SAM to the DNA, Dnmt1 produces the by-
product SAH, a potent inhibitor of Dnmt1.  Any interruption of the methylation 
cycle affecting production of SAM will decrease DNA methylation.  Furthermore, 
an increase in the metabolite homocysteine favors SAH synthesis thereby 
decreasing DNA methylation through Dnmt1 inhibition. 
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 Most CG pairs in DNA are methylated except in and around active 
promoter regions.  Methylation of promoter regions generally corresponds to 
transcriptionally inactive genes whereas unmethylated promoters are associated 
with active gene transcription.  In lupus, several methylation-sensitive immune 
genes, such as CD11a, CD70, KIR, and perforin, are overexpressed due to 
hypomethylation of CD4+ T cell DNA [175].  The overexpression pattern is 
identical to that seen in normal CD4+ T cells treated with DNA methylation 
inhibitors.  Furthermore, the genes that are overexpressed are demethylated at 
their promoters in both the lupus T cells and the experimentally demethylated T 
cells, compared to normal T cells.  The overexpression of these genes in CD4+ T 
cells has functional consequences such as macrophage apoptosis and 
autoantibody production caused by the altered T cells, which may in part be 
responsible for disease pathogenesis. 
 We hypothesized that the T cell hypomethylation seen in lupus patients 
may be due in part to changes in serum/plasma levels of key micronutrients 
involved in the methylation cycle.  We therefore obtained blood from lupus 
patients and compared the serum or plasma levels of seven micronutrients and 
homocysteine to the normal population values.  The results suggest that 
subclinical deficiencies in certain micronutrients may play a role in lupus due to 
potential alterations of the methylation cycle. 
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Materials and Methods 
Human Subjects.  The University of Michigan Institutional Review Board for 
Human Subject Research reviewed and approved this study.  Patient samples 
were collected from the University of Michigan outpatient clinic with informed 
consent according to the Declaration of Helsinki.  Patient characteristics are 
listed in Table 2.1.  Subjects were questioned regarding vitamin supplements, 
fasting status, and alcohol consumption for the 24 hour period preceeding 
sample collection since these may affect test results.  In most cases we were not 
able to collect fasting samples, however we did take note of any patients that 
may have already been fasting. 
 
Sample processing.  A total of 37 milliliters (mls) of blood was collected in green  
top (sodium heparin) Vacutainer tubes for methionine, choline, riboflavin, and 
vitamin B6 testing, SST™ Vacutainer tubes for folate and vitamin B12 testing, 
lavender top (EDTA) Vacutainer tubes for homocysteine testing, and royal blue 
(no additive) tubes for zinc testing.  Plasma or serum was extracted within 30 
minutes of blood collection by centrifugation.  Samples were then aliquoted and 
frozen at -20°C until analysis. 
 
Sample testing.  Serum folate, zinc, and vitamin B12 were measured by the 
University of Michigan Chemical Pathology Laboratories.  Plasma homocysteine, 
riboflavin, and vitamin B6 were also measured by the University of Michigan 
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Chemical Pathology Laboratories.  Plasma methionine was measured by the 
Mayo Medical Laboratories.  Plasma choline was measured by Ralston Analytical 
Laboratories.  Test methodology is listed in Table 2.2. 
 
SLEDAI score.  To compare disease activity, the Systemic Lupus 
Erythematosus Disease Activity Index (SLEDAI) was used [176] (Table 2.3).  A 
score was assigned to each patient based on clinical lab findings and physician‟s 
findings within the past 10 days of sample collection.  The portion of the score 
based on the doctor‟s note may be subjective, therefore scores that were not 
definitive were confirmed by the physician in charge of the lupus cohort who 
independently assigned a score. 
 
Statistical Analysis.  To compare the levels of different micronutrients in the 
lupus patients to the normal population values, the mean of the lupus patients' 
value was compared to the midpoint of the normal range, using a one-sample t-
test. For non-normally distributed variables, the median of the micronutrient value 
was compared to the midpoint of the normal range using a non-parametric 
Wilcoxon sign rank test. 
The percentage of patients who were out of the normal range (either above or 
below the normal range) was assessed using a one-sample binomial proportion, 
and a 95% confidence interval was computed. 
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Statistical analyses were conducted using IBM SPSS Statistics, version 21 for 
Windows, copyright  IBM corporation 1989, 2012. 
 
Results 
Serum/plasma nutrient concentrations.  Serum folate, zinc, and vitamin B12, 
and plasma homocysteine, riboflavin, vitamin B6, and methionine were tested in 
28-35 lupus patients and compared to the mean population reference values 
given by each laboratory.  Mean population reference values have been 
established from historical data spanning large population groups.  Plasma 
choline was tested in 10 lupus patients and compared to 10 age- and gender-
matched controls (Table 2.4).  Serum zinc levels were significantly decreased in 
lupus patients compared to the normal female population mean value for zinc 
concentration (0.71 vs 0.86; p=0.0001).  Vitamin B6 was also decreased in the 
lupus patients tested compared to the mean population value (16.48 vs. 22.5; 
p=0.021).  Homocysteine was significantly increased in lupus patients compared 
to the mean population value (11.37 vs. 9.5; p=0.013).  Methionine was also 
significantly decreased in lupus patients compared to the mean population value 
(23.09 vs. 26.0; p-0.012).  There were no significant differences in serum folate 
and vitamin B12, and plasma riboflavin in lupus patients compared to the mean 
population value.  There was also no significant difference in plasma choline 
levels in the ten lupus patients tested compared to ten age- and gender- matched 
controls.  These results were independent of age and disease activity. 
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Discussion 
 These studies indicate lower than average levels of zinc, vitamin B6, and 
methionine, and higher homocysteine levels in lupus patients compared to the 
normal population.  While the changes seen here are within the normal ranges 
established, the possibility of subclinical changes in dietary micronutrients having 
metabolic effects has been raised [73]. 
 The change in zinc was small but significant compared to the normal 
population.  Considering plasma zinc is under close homeostatic control [73], the 
decrease may have implications for pathogenesis.  The role of zinc has been well 
established in numerous immune functions including effects on T lymphocytes 
[177].  Responses involving T lymphocytes such as delayed hypersensitivity and 
cytotoxic activity are impaired during zinc deficiency and restored by zinc 
supplementation [178-181].  T cell proliferative responses to mitogens such as 
PHA are reduced during zinc deficiency, as in the case of patients receiving total 
parenteral nutrition devoid of zinc [130].  Importantly, zinc may alter T cell surface 
molecules.  Pretreatment of T lymphocytes with zinc in vitro enhanced rosetting 
by sheep erythrocytes [182].  Furthermore, zinc was shown to increase 
transcription and expression of ICAM-1, an adhesion molecule, on the surface of 
lymphocytes [183].  Other lymphocyte surface molecules have been reported to 
be altered in SLE due to hypomethylation [184].  Zinc may contribute to these 
changes due to its role in the methylation cycle.  Zinc is important in the 
regeneration of methionine in the methylation cycle.  Two key enzymes utilize 
zinc to remethylate homocysteine to form methionine.  Methionine is necessary 
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for the formation of the methyl donor SAM, therefore a decrease in zinc has 
potential for interrupting methylation. 
 We also found vitamin B6 and methionine to be decreased in lupus 
patients compared to the means of the normal population.  As mentioned above, 
methionine is essential for maintaining the methylation cycle through formation of 
SAM.  Vitamin B6 is necessary for the conversion of homocysteine to cystathione 
and a decrease in vitamin B6 results in elevated homocysteine levels.  Vitamin 
B6 levels decrease with age and evidence of potential widespread subclinical 
deficiency has been reported [73].  Interestingly, a study by Mohan et al. has 
recently also reported decreased vitamin B6 and methionine levels in lupus 
patients [185].  In the study, the authors used an LC/MS and GC/MS based 
platform to perform a comprehensive metabolic scan of sera from 20 SLE 
patients and 9 healthy controls.  They found a decrease in methionine levels, and 
a decrease in vitamin B6 levels that correlated with disease activity.  They further 
validated the vitamin B6 decrease using an independent cohort of 38 SLE 
patients and 14 healthy controls.  These results are corroborated by our findings 
that vitamin B6 and methionine are decreased in lupus patients. 
 Homocysteine levels were increased in lupus patients compared to the 
normal population in our study.  This is in accordance with a previous study also 
demonstrating increased homocysteine levels in lupus patients [79].  
Homocysteine is a key metabolite in the methylation cycle, where it is 
remethylated by methionine synthase and 5-methylTHF as the methyl donor to 
form methionine.  An increase in homocysteine results in increased synthesis of 
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SAH, a potent inhibitor of methylation [68].  Vitamin B6 is involved in the 
metabolism of homocysteine and as stated above, was decreased in our study.  
Interestingly, the decrease in vitamin B6 along with an increase in homocysteine 
is similar to the results of a prospective study of lupus patients [79].  In the 
prospective study, elevated homocysteine levels correlated with risk of stroke 
and arterial thrombotic events in patients with SLE after adjusting for established 
risk factors.  Elevated homocysteine concentrations have also been associated 
with atherosclerosis and thrombotic events in the elderly [186-189].  In the 
Framingham Heart Study, homocysteine concentrations above 14.1 μmol/L were 
found in 29.3% of the study population with 67% of the high homocysteine cases 
attributable to low plasma concentrtions of folate, vitamin B12, and PLP (vitamin 
B6) [190].  Since vascular thrombotic events are a major contributor to morbidity 
and mortality in SLE and homocysteine is a modifiable risk factor that plays a role 
in methylation, our findings reiterate the potential importance that vitamin 
intervention may have in SLE. 
 Folate was not decreased in our study, contrary to what we might have 
expected.  Folate is an important methyl donor In the methylation cycle and is 
well known to affect methylation.  Considering lupus patients have 
hypomethylated T cell DNA, we hypothesized that they may have lower than 
average folate levels.  Furthermore, homocysteine is a sensitive indicator of 
folate status [73], and since homocysteine was elevated in our cohort of patients, 
we expected folate levels to be decreased.  Importantly, in a study by Petri et al., 
decreases in folate levels did correlate with the elevated homocysteine levels 
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seen in lupus patients [79].  The difference may be due to the patient population 
studied.  In the study by Petri et al., a large number of patients was studied (337), 
allowing capture of several patients with high homocysteine levels: 15% (51) of 
the patients had homocysteine concentrations above 14.1 μmol/L.  Furthermore, 
in our study, the average SLEDAI score, an index used to assess disease activity, 
was 3, which is considered inactive disease.  Studying patients with more active 
disease and higher SLEDAI scores may yield higher homocysteine levels and 
corresponding decreases in folate levels.  Additionally, we questioned our 
patients regarding vitamin/folate supplementation and alcohol consumption in the 
24 hours preceeding the test, since these affect test results however due to the 
widespread fortification of foods with folic acid in the US, it is difficult to control for 
dietary intake.  We used plasma folate as a measure of folate levels in our study 
based on guidelines from the University of Michigan Chemical Pathology 
Laboratories, however it has been suggested that red blood cell folate may be a 
more accurate measure of folate since plasma folate is subject to greater 
fluctuation [74]. 
 We didn‟t observe any difference in the vitamin B12 levels in lupus 
patients compared to the normal population.  Vitamin B12 is involved in the 
metabolism of homocysteine and levels of vitamin B12 correlated with increased 
homocysteine levels in the Framingham Heart Study [190].  However, the 
Framingham population is elderly, and vitamin B12 deficiency can occur in the 
elderly because of malabsorption due to atrophic gastritis, whereas our study 
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population was an average age of 33 years.  This, along with a low average 
SLEDAI score may explain the lack of change seen in our study. 
 There was no difference in choline levels, though this may be due to our 
small sample number of 10 patients and 10 controls.  Mohan et al., did observe a 
reduction in choline levels in lupus patients which was accompanied by 
decreased phosphocholine levels [185]. 
 Our study and the study by Mohan et al., did not demonstrate any change 
in the riboflavin levels of lupus patients compared with controls. 
 In conclusion, we found decreases in zinc, methionine, and vitamin B6, 
and an increase in homocysteine levels in lupus patients compared to the normal 
population.  The decreases in methionine and vitamin B6 and the increase in 
homocysteine that we observed corroborate findings from other studies, in a 
different cohort of patients [79, 185].  This is however the first study to note a 
change in zinc levels in lupus patients compared to the normal population.  The 
major limitations of our study were the low SLEDAI scores of the patients and 
possibly the sample size.  The micronutrients studied here are key players in the 
methylation cycle and are potentially modifiable through dietary intervention, 
therefore deserve further study into potential benefits for autoimmunity. 
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No. 37 
Female, no. 35 
Age, mean, years (range) 40 (21-79) 
Race  
    Caucasian 30 
    African-American 6 
    Hispanic 1 
SLEDAI, mean (range) 3 (0-12) 
 
Table 2.1:  Patient characteristics 
 
 
 
Methionine HPLC 
Homocysteine Chemiluminescent Assay 
Folate Chemiluminescent Immunoassay 
Choline Enzymatic assay based on oxidation by choline oxidase 
Vitamin B12 Chemiluminescent Immunoassay 
Zinc Atomic Absorption 
Vitamin B6 Liquid Chromatography-Tandem Mass Spectrometry 
Riboflavin Liquid Chromatography-Tandem Mass Spectrometry   
 
Table 2.2: Test methodology 
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Table 2.3:  SLEDAI criteria 
https://www.rheumatology.org/Practice/Clinical/Indexes/Systemic_Lupus_Erythematosus_Disease_Activity_I
ndex_SELENA_Modification/ 
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Table 2.3: SLEDAI criteria continued 
https://www.rheumatology.org/Practice/Clinical/Indexes/Systemic_Lupus_Erythematosus_Disease_Activity_I
ndex_SELENA_Modification/ 
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Table 2.4: Serum/plasma nutrient concentrations in lupus 
petients vs. population.  *N=28-35 patients; choline=10 patients 
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CHAPTER III: MICRONUTRIENT LEVELS MODULATE METHYLATION-
SENSITIVE GENE EXPRESSION IN T CELLS 
 
Introduction 
 The methylation cycle is dependent on several dietary micronutrients and 
metabolites.  Micronutrient levels affecting methylation have been studied in 
various aspects of health and disease.  Recently, the importance of maternal 
nutrition affecting epigenetic patterns established in utero and the consequent 
lifelong impacts has garnered significant interest in the field of developmental 
origins of health and disease (DOHaD).   Epigenetic changes due to 
micronutrients have been studied in the field of cancer as well [191-195].  
Autoimmunity is also affected by DNA methylation, however epigenetic changes 
in immune cells due to micronutrient alterations is poorly understood. 
 It has been well established that CD4+ T cell hypomethylation occurs in 
SLE, a prototypic autoimmune disease [184].  This has been shown in terms of 
global methylation [42] as well as gene-specific hypomethylation [45, 58-60].  
The hypomethylation causes overexpression of immune-relevant methylation-
sensitive genes with functional consequences.  CD70 is a B cell costimulatory 
molecule whose overexpression results in increased antibody production [51].  
KIR and perforin are not normally expressed in T cells, but are aberrantly 
expressed due to hypomethylation of their gene promoter regions, resulting in 
effects including macrophage killing [58, 62].  The functional consequences of 
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these overexpressed genes likely contributes to lupus pathogenesis.  We 
therefore sought to determine whether changes in micronutrient levels could 
affect methylation-sensitive gene expression in T cells. 
 When studying methylation in vitro, effects may be masked by the large 
quantities of pro-methylation micronutrients present in the tissue culture medium.  
We developed a custom media containing transmethylation micronutrient levels 
that were similar to physiologic levels.  We then compared T cell methylation-
sensitive gene expression in custom media and the standard media.  The results 
suggest that micronutrient levels do in fact modify T cell gene expression and 
that conventional tissue culture medium may conceal some of the effects. 
 
Materials and Methods 
Reagents.  RPMI 1640 was purchased from Invitrogen Life Technologies.  RPMI 
1640 without vitamin B6, methionine, folic acid, vitamin B12, riboflavin, and 
choline was custom ordered from Invitrogen Life Technologies.  Zinc, vitamin B6, 
methionine, folate, vitamin B12 and riboflavin were also purchased from 
Invitrogen Life Technologies.  Homocysteine was purchased from Sigma.  Ficoll 
Paque Plus was purchased from GE Healthcare, phytohemagglutinin was 
purchased from Remel, and recombinant human IL-2 was purchased from 
Peprotech.  Antibodies were purchased from BD Pharmingen, Beckman Coulter, 
and R & D Systems.  Cytofix/Cytoperm Kit was purchased from BD Biosciences.  
Standardization particles were purchased from Bangs Laboratories.  Magnetic 
beads were purchased from Miltenyi Biotech, SV Total RNA Isolation System 
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was purchased from Promega Corporation, and QuantiTect SYBR Green RT-
PCR kit was purchased from Qiagen. 
Human subjects.   The University of Michigan Institutional Review Board for 
Human Subject Research reviewed and approved this study.  Healthy donors 
were recruited by advertising.  Both male and female donors were utilized, 
ranging in age from 18-45. 
Custom media.  Custom media was created using RPMI 1640 without vitamin 
B6, methionine, folate, vitamin B12, riboflavin, and choline as the base.  Vitamin 
B6, methionine, folate, vitamin B12, riboflavin, and choline were added back at 
concentrations adjusted to physiologic levels, listed in Table 3.1.  Homocysteine 
and zinc were also added at physiologic concentrations (Table 3.1).  Fetal bovine 
serum was dialyzed against Hank‟s Balanced Salt Solution (HBSS) using 
SpectraPor dialysis tubing with a molecular weight cutoff of 2,000 to exclude 
additional micronutrients. 
Cell culture.  Human peripheral blood mononuclear cells (PBMCs) were isolated 
using Ficoll-Paque Plus density gradient centrifugation.  Cells were cultured at 
1x106/mL in RPMI 1640 with 10% fetal bovine serum (FBS) or custom media with 
10% dialyzed FBS.  Phytohemagglutin (PHA) was added at a concentration of 
1μg/mL for 18-24hrs to stimulate T cells.  Cells were washed and cultured for an 
additional 3 days in their respective culture media without PHA.  Cells were then 
harvested for flow cytometric or real-time RT-PCR analysis.   
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Flow cytometry.  Extracellular cell surface staining was performed using human 
antibodies for CD11a, CD70 and KIR.  Since the KIR molecules belong to a 
family of polymorphic genes, a cocktail of KIR antibodies reactive to various KIR 
receptors was used: CD158b1/b2,j; CD158i; NKB1; CD158b; CD158a,h; 
KIR2DL4/CD158d.  Intracellular staining was performed using a human perforin 
antibody and the Cytofix/Cytoperm Kit.  Cells were stained and fixed, then 
analyzed on a FACSCalibur flow cytometer at least 24 hours later to allow for cell 
equilibration after contraction due to fixing.  Isotype and single-color positive 
controls were included in each condition.  Standardization particles for 
fluorescein isothiocyanate (FITC), phycoerythrin (PE) and cychrome (CYC) were 
run during each experiment for instrument calibration.  Ten thousand events in 
the gated lymphocyte population were captured.  Percent-positive cells were 
assessed for CD70, KIR and perforin.  Mean fluorescence intensity was 
assessed for CD11a and CD70.  Flow cyometric results were analyzed using 
FCS Express Software, version 3 (De Novo™ Software, Los Angeles, CA). 
Real-time RT-PCR.  Total RNA was isolated using the Promega SV Total RNA 
Isolation System.  CD4+ and CD8+ T cells were isolated using magnetic bead 
purification.  CD70, perforin, and β-actin transcripts were then measured using a 
Rotor-Gene 3000 (Corbett Robotics, San Francisco, CA) and the QuantiTect 
SYBR Green RT-PCR kit according to the manufacturers‟ instructions.  CD70, 
perforin, and β-actin primer sequences were as previously published [51, 58]. 
Statistical analysis.  A linear mixed model (LMM) was used to estimate the 
linear relationship between micronutrient concentration and gene expression.   A 
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random effect was included for each subject, to take into account that there were 
multiple concentrations measured for each subject.  Statistical analyses were 
conducted using IBM SPSS Statistics, version 21 for Windows, copyright IBM 
corporation 1989, 2012. 
 
Results 
RPMI 1640 is associated with decreased protein expression of methylation-
sensitive T cell genes.  RPMI 1640 contains high levels of pro-methylation 
micronutrients, therefore we developed a custom media with physiologic levels of 
transmethylation micronutrients (Table 3.1) to study the expression of 
methylation-sensitive T cell genes.  PBMCs were isolated from 9 different healthy 
donors and cultured as described in “Materials and Methods” section.  Cells were 
then harvested and stained with antibodies for CD11a, CD70, KIR, and perforin 
along with either CD4 or CD8, and analyzed by flow cytometry.  Multiple repeats 
were performed on several donors; in those cases, an average value for 
expression was calculated for each donor.  In CD4+ T cells, KIR and perforin had 
significantly higher expression (p=0.016; p=0.001, respectively) in custom media 
relative to RPMI 1640.  In CD8+ T cells, CD70, KIR, and perforin had significantly 
higher expression (p=0.004; p=0.001; p=0.004, respectively) in custom media 
relative to RPMI 1640 (Figure 3.1).  No change was observed in CD11a 
expression (data not shown). 
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RPMI 1640 is associated with decreased CD70 and perforin mRNA 
expression.  We examined mRNA expression of two methylation-sensitive 
genes in CD4+ T cells cultured in RPMI 1640 compared to custom media.  
PBMCs were isolated from 5 different healthy donors and cultured as described 
in “Materials and Methods” section.  Cells were then harvested and separated 
into CD4+ and CD8+ T cell subsets by positive selection using magnetic bead 
purification.  Total RNA was extracted and transcripts were measured using 
Real-time RT-PCR.  CD70 and perforin mRNA expression in CD4+ T cells was 
significantly increased (p=0.02; p-0.04, respectively) in custom media compared 
to RPMI 1640.  Perforin mRNA expression was significantly increased (p=0.03) in 
CD8+ T cells compared to RPMI 1640 (Figure 3.2). 
 
Increasing folate suppresses perforin expression.  To investigate individual 
micronutrient effects on methylation-sensitive gene expression, custom media 
was used, varying the concentration of one micronutrient at a time.  PBMCs were 
isolated from 3 different healthy donors and cultured in RPMI 1640 or custom 
media with varying concentrations of folic acid, as described in “Materials and 
Methods” section.  Cells were then harvested and intracellularly stained with the 
perforin antibody, and analyzed by flow cytometry for protein expression.  Folate 
levels that were increased above the normal physiologic range caused a 
significant suppression of perforin expression in CD4+ (p=0.006) and CD8+ 
(p=0.006) T cells (Figure 3.3). 
 48 
 
 
Increasing vitamin B6 decreases perforin expression.  The effect of vitamin 
B6 on T cell methylation-sensitive gene expression was also studied.  PBMCs 
were isolated from 4 different healthy donors and cultured in RPMI 1640 or 
custom media with varying concentrations of vitamin B6, as described in 
“Materials and Methods” secton.  Cells were then harvested and intracellularly 
stained with the perforin antibody, and analyzed by flow cytometry for protein 
expression.  CD4+ T cells had a significant decrease (p=0.032) in perforin 
expression when exposed to higher concentrations of vitamin B6.  There was no 
significant effect in CD8+ T cells (Figure 3.4). 
 
Increasing homocysteine causes CD70 overexpression.  Since homocysteine 
levels can interrupt the methylation cycle by favoring synthesis of SAH, an 
inhibitor of Dnmt1 [68], we examined the effects of increasing homocysteine on 
methylation-sensitive gene expression in T cells.  PBMCs were isolated from 4 
different healthy donors and cultured in RPMI 1640 or custom media with varying 
concentrations of homocysteine, as described in “Materials and Methods” section.  
Cells were then harvested and stained with anti-CD70 and analyzed by flow 
cytometry for protein expression.  CD4+ and CD8+ T cells had a significant 
increase (p=0.005; p=0.045, respectively) in CD70 expression when exposed to 
increasing homocysteine concentrations (Figure 3.5).  
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Discussion 
 These studies demonstrate that altered levels of micronutrients can 
modulate immune- relevant methylation-sensitive gene expression in T cells.  
Conventional tissue culture media such as RPMI 1640 contain high levels of 
transmethylation micronutrients that may favor methylation, thus masking 
methylation effects (Table 3.1).  For example, the level of methionine found in 
RPMI 1640 is approximately 3 times the level present in human serum, while 
folate in RPMI 1640 is approximately 56 times the level found in human serum.  
We developed a custom media where key micronutrients involved in the 
methylation cycle are adjusted to physiologic levels.  Zinc and homocysteine are 
two important metabolites involved in the methylation cycle but not present in 
RPMI 1640.  We therefore added zinc and homocysteine to our custom media at 
physiologic levels to study their effects as well.  
 Our results show significant increases in CD70, KIR, and perforin protein 
expression in the custom media (Figure 3.1), supporting the hypothesis that 
micronutrient levels alter methylation-sensitive gene expression in T cells.  
Furthermore, the results suggest that RPMI 1640 may conceal methylation-
related effects in T cells studied in vitro.  We also examined mRNA expression of 
CD70 and perforin in custom media versus RPMI 1640.  CD70 and perforin 
mRNA expression was significantly increased in custom media compared to 
RPMI 1640 (Figure 3.2), corroborating our protein data. 
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 Based on the results using custom media, we investigated which particular 
micronutrients in the media may be affecting expression of methylation-sensitive 
genes in T cells.  To do this, we used the custom media with all transmethylation 
micronutrients of interest at physiologic levels, with one being varied at a time, 
spanning concentrations below and above the physiologic range.  We varied 
each of the 8 micronutrients of interest and examined the protein expression of 
the 4 immune-relevant methylation-sensitive genes.  We found significant effects 
with folate, vitamin B6, and homocysteine.  Perforin expression was decreased in 
CD4+ and CD8+ T cells when folate concentration was increased.  Perforin 
expression was also decreased in CD4+ T cells when vitamin B6 levels were 
increased.  Increasing homocysteine concentration in the custom media caused 
overexpression of CD70.  The other micronutrient and gene combinations had no 
significant effects in this system (data not shown). 
 These data suggest an important role of micronutrients in the expression 
of methylation-sensitive genes in T cells.  As noted earlier, the genes studied are 
overexpressed in SLE, therefore micronutrient modulation of their expression is 
of particular interest since dietary modification may have potential benefits.  In 
the first portion of this study, custom media altered the expression of CD70, KIR 
and perforin compared to RPMI 1640, demonstrating modulation by 
micronutrients.  Additionally, the study suggests limitations of conventional tissue 
culture media when studying methylation-related changes.  Indeed, methylation 
changes due to tissue culture media composition have been implicated in 
assisted reproductive technology (ART).  Beckwith-Wiedemann syndrome, a 
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disorder characterized by overgrowth and neoplasia due to aberrant methylation 
and imprinting of a group of genes, has been linked to ART.  The changes may 
be due to culture conditions, including media, and potentially other aspects of the 
ART [196]. 
 In the second portion of this study where individual micronutrients were 
varied one at a time, three micronutrients emerged as having clear effects on 
protein expression: folate, vitamin B6, and homocysteine.  Folate and vitamin B6 
are well known to be involved in the metabolism of homocysteine.  Interestingly, 
in Chapter 2 of this dissertation, we studied serum levels of micronutrients in 
lupus patients and found vitamin B6 to be decreased and homocysteine to be 
increased compared to the normal population.  We did not observe a change in 
folate levels likely due to the limitations of our study, however Petri et al., did find 
high homocysteine levels to be associated with folate and vitamin B6 levels in a 
cohort of lupus patients [79].  We also observed decreased zinc and methionine 
in the serum of lupus patients (Chapter 2), but did not observe any significant 
effects on T cell methylation-sensitive gene expression in the present study.  This 
may be due to the limitations of a cell culture system where cell-cell or tissue-
tissue interactions are missing.  Methionine is an essential amino acid and an 
essential component of tissue culture media; it is possible that decreasing 
methionine in the presence of other decreased transmethylation micronutrients 
may cause suboptimal culture conditions.  Zinc is not normally added to tissue 
culture media and can be detrimental in too high concentrations in tissue culture.  
This may also result in suboptimal tissue culture conditions.  Additionally, zinc is 
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maintained under very close homeostatic control in the body which is not 
replicated in an in vitro system.  Nevertheless, these studies suggest an 
important role for folate, vitamin B6, and homocysteine in methylation-sensitive 
gene expression in T cells with potential implications for lupus pathogenesis.  
Several mechanisms may be involved in the altered micronutrient effects on 
methylation-sensitive gene expression.  For example, the altered micronutrients 
may be altering the SAM/SAH ratio, thus affecting methylation.  Measurements of 
SAM and SAH levels will help to determine this.  Further, it is possible that 
changes in transport and metabolism of the micronutrients and not the quantities 
themselves are resulting in the methylation-sensitive gene expression changes 
seen.  Studies in which additional information from donors such as the presence 
of SNPs involved in micronutrient metabolism and hypermethylation of genes 
involved in folate biosynthesis pathways can be correlated with altered 
micronutrient-induced methylation-sensitive gene expression in vitro, will aid in 
establishing the mechanisms involved. 
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  Table 3.1:  Comparison of transmethylation micronutrient 
levels in RPMI 1640, human serum, and custom media. 
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Figure 3.1 RPMI 1640 is associated with decreased protein 
expression of methylation-sensitive T cell genes.  PBMCs were 
isolated from 9 different healthy donors and cultured in either RPMI 
1640 or custom media, as described in “Materials and Methods” 
section.  After culture, cells were stained with antibodies and 
analyzed by flow cytometry.  Results are shown relative to 
expression in RPMI 1640.  KIR and perforin expression in CD4+ T 
cells were significantly increased in custom media compared to 
RPMI 1640.  CD70, KIR and perforin expression in CD8+ T cells 
were significantly increased in custom media compared to RPMI 
1640. 
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Figure 3.2  RPMI 1640 is associated with decreased CD70 and 
perforin mRNA expression.  PBMCs were isolated from 5 healthy 
donors and cultured in either RPMI 1640 or custom media as 
described in “Materials and Methods” section.  After culture, cells 
were separated into CD4+ and CD8+ subsets, total RNA was 
extracted and analyzed by Real-time RT-PCR.  Results are shown 
relative to expression in RPMI 1640.  CD70 and perforin mRNA 
expression was significantly increased in both CD4+ and CD8+ T 
cells cultured in custom media compared to RPMI 1640. 
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Figure 3.3  Increasing folate suppresses perforin protein 
expression.  PBMCs were isolated from 3 healthy donors and 
cultured in RPMI 1640, or custom media with varying 
concentrations of folic acid, as described in “Materials and 
Methods” section.  After culture, cells were stained with antibodies 
for CD4 or CD8, and perforin.  Black horizontal shaded bar 
represents physiologic range of folate.  Results are standardized to 
RPMI 1640 and are shown as mean ± SEM.  Higher 
concentrations of folate significantly decreased perforin expression 
in both CD4+ and CD8+ T cells. 
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Figure 3.4  Increasing vitamin B6 decreases perforin protein 
expression.  PBMCs were isolated from 4 healthy donors and 
cultured in RPMI 1640, or custom media with varying 
concentrations of vitamin B6, as described in “Materials and 
Methods” section.  After culture, cells were stained with antibodies 
for CD4 or CD8, and perforin.  Black horizontal shaded bar 
represents physiologic range of vitamin B6.  Results are 
standardized to RPMI 1640 and are shown as mean ± SEM.  
Higher concentrations of vitamin B6 significantly decreased 
perforin expression in CD4+ T cells. 
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  Figure 3.5  Increasing homocysteine leads to CD70 protein 
overexpression.  PBMCs were isolated from 4 healthy donors and 
cultured in RPMI 1640, or custom media with varying 
concentrations of homocysteine, as described in “Materials and 
Methods” section.  After culture, cells were stained with antibodies 
for CD4 or CD8, and CD70.  Black horizontal shaded bar 
represents physiologic range of homocysteine.  Results are 
standardized to RPMI 1640 and are shown as mean ± SEM.  
Higher concentrations of homocysteine significantly increased 
CD70 expression in CD4+ and CD8+ T cells. 
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CHAPTER IV: OXIDANTS AND ALTERED MICRONUTRIENT LEVELS 
SYNERGIZE TO ALTER METHYLATION-SENSITIVE GENE EXPRESSION IN 
T CELLS. 
 
 
Introduction 
 Oxidative stress is defined as an imbalance between oxidants and 
antioxidants in favor of the oxidants, leading to a disruption of redox signaling 
and control and/or molecular damage [142].  Oxidative stress has been 
implicated in lupus pathogenesis.  Several markers of oxidative stress are 
elevated in lupus patients including urinary F2 isoprostane [150], protein 
carbonyls [149], and 3-nitrotyrosine [151].  Interestingly, protein carbonyl and 
3NT levels correlated with disease activity, and protein carbonyl levels were 
increased in patients with organ damage compared to those without [152]. 
 3-nitrotyrosine is formed when tyrosine residues are nitrated by 
peroxynitrite (ONOO-).  Nitration of proteins is one method by which oxidative 
stress may be contributing to lupus.  The highly reactive ONOO- is formed when 
nitric oxide combines with superoxide anion.  The increased NO levels present in 
lupus patients [151, 157] may be causing increased nitration of proteins [149, 
151] through formation of ONOO- [197].  Recent evidence has suggested that 
cytotoxicity caused by NO may in fact be due to the effects of ONOO-[197]. 
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 Nitration of proteins has recently been linked to epigenetic mechanisms 
contributing to lupus.  Decreased DNA methylation resulting in overexpression of 
several immune-related genes has been associated with SLE [105].  DNA 
methylation is regulated in part by the Dnmt enzymes.  In lupus, Dnmt1 levels are 
decreased due to defective ERK pathway signaling [170].  The defect has been 
traced to impaired phosphorylation of the PKCδ isoform [55] which is upstream of 
ERK.  Subsequent studies revealed that nitration of PKCδ is responsible for the 
aberrant PKCδ phosphorylation [56] and likely the ERK pathway signaling 
abnormalities associated with decreased Dnmt1 levels. 
 DNA methylation is also affected by dietary nutrients involved in the 
transmethylation pathway.  Two metabolites of particular interest are folate and 
methionine.  The main methyl group donor for most biological methylation 
reactions is S-adenosylmethionine (SAM).  SAM is formed from methionine and 
ATP by the enzyme methionine adenosyltransferase (MAT).  Methionine, along 
with N-methyltetrahydrofolate and choline are the primary dietary sources of 
methyl groups (~10, 5, and 30 mmol methyl/d, respectively) [198].  Since 
methionine is an essential amino acid and cannot be synthesized de novo in 
humans, dietary intake is likely indispensable for maintaining SAM levels [199].  
S-adenosylhomocysteine (SAH) is the by-product of DNA methylation by SAM 
and an inhibitor of Dnmt [68].  SAH can then be hydrolyzed to adenosine and 
homocysteine.  Folate is important in the remethylation of homocysteine to 
methionine [110].  Elevated homocysteine has been associated with disease 
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states such as atherosclerosis [200] and uremia [201], and is a strong indicator of 
folate status [73]. 
 Based on the knowledge that lupus patients have increased oxidative 
stress and altered T cell DNA methylation patterns, and that folate and 
methionine play a role in the methylation cycle, we hypothesize that oxidative 
stress and decreases in folate or methionine may be synergistic in causing 
overexpression of methylation-sensitive genes.  We therefore cultured T cells 
from normal healthy donors in media containing altered folate or methionine, 
treated them with variable concentrations of ONOO- and examined expression of 
methylation-sensitive genes.  The results suggest a potential additive effect of 
oxidative stress and decreased methyl donors, which may have implications for 
autoimmunity. 
 
 
Materials and Methods 
Reagents.  RPMI 1640, RPMI1640 without folate and RPMI 1640 without 
methionine,and folate and methionine were all purchased from Invitrogen Life 
Technologies; Ficoll-Paque Plus was purchased from GE Healthcare; 
phytohemagglutinin was purchased from Remel; recombinant human IL-2 was 
purchased from Peprotech; and peroxynitrite was purchased from Calbiochem.  
Antibodies were purchased from BD Pharmingen, Beckman Coulter and R & D 
Systems.  Cytofix/Cytoperm Kit was purchased from BD Biosciences.  
Standardization particles were purchased from Bangs Laboratories. 
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Human subjects.  The University of Michigan Institutional Review Board for 
Human Subject Research reviewed and approved this study.  Healthy donors 
were recruited by advertising.  Average age of donors for folate studies was 31, 
ranging from 22-37 (n=6; 2 males, 4 females).  Average age of donors for 
methionine studies was 33, ranging from 29-37 (n=6; 1 male, 5 female). 
 
Cell culture and treatment.  Human peripheral blood mononuclear cells 
(PBMCs) were isolated using Ficoll-Paque Plus density gradient centrifugation.  
Cells were cultured at 1x106/ml in RPMI 1640 with 10% fetal bovine serum (FBS), 
and 1µg/ml phytohemagglutinin, for 18-24hrs.  Cells were then washed and 
incubated with RPMI 1640 and either RPMI 1640 without folate or RPMI 1640 
without methionine, regular or dialyzed FBS, 10ng/ml recombinant human IL-2, 
and 0, 20 or 25µM peroxynitrite (Appendix A) for 3 days.  Cells were then 
harvested and washed for flow cytometric analysis. 
 
Flow cytometry.  Extracellular cell surface staining was performed using human 
antibodies for CD11a, CD70 and KIR.  Since the KIR molecules belong to a 
family of polymorphic genes, a cocktail of KIR antibodies reactive to various KIR 
receptors was used: CD158b1/b2,j; CD158i; NKB1; CD158b; CD158a,h; 
KIR2DL4/CD158d.  Intracellular staining was performed using a human perforin 
antibody and the Cytofix/Cytoperm Kit.  Cells were stained and fixed, then 
analyzed on a FACSCalibur flow cytometer at least 24 hours later to allow for cell 
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equilibration after contraction due to fixing.  Isotype and single-color positive 
controls were included in each condition.  Standardization particles for 
fluorescein isothiocyanate (FITC), phycoerythrin (PE) and cychrome (CYC) were 
run during each experiment for instrument calibration.  Ten thousand events in 
the gated lymphocyte population were captured.  Percent-positive cells were 
assessed for CD70, KIR and perforin.  Mean fluorescence intensity was 
assessed for CD11a and CD70.  Flow cyometric results were analyzed using 
FCS Express Software, version 3 (De Novo™ Software, Los Angeles, CA). 
 
 
Statistical analysis.  A repeated measures ANOVA was used to analyze the 
relationship between the three folate concentrations (2270nM, 40nM, 10nM) or 
three methionine concentrations (101µM, 30µM, 5µM), and the three 
peroxynitrite concentrations (0µM, 20µM, 25µM) on gene expression among 
normal subjects. Because cells from each subject received all combinations of 
folate or methionine and peroxynitrite, we included folate or methionine 
concentration and peroxynitrite concentration plus their interaction as the within-
subjects effects. Post-hoc tests, with a Bonferroni correction for multiple 
comparisons, were used to examine the specific effects of peroxynitrite at each 
given concentration of folate or methionine and the specific effects of folate or 
methionine at each level of peroxynitrite.  Statistical analyses were conducted 
using IBM SPSS Statistics, version 21 for Windows, copyright IBM corporation 
1989, 2012. 
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Results 
Peroxynitrite and folate treatment.  CD4+ T cells cultured in 40nM and 10nM 
folate concentrations increased expression of CD70, as compared to the 
standard media, RPMI 1640.  Simultaneous treatment with 20µM and 25µM 
peroxynitrite further increased the expression of CD70 (Figure 4.1A; p<0.001 for 
overall folate effect; p<0.001 for overall peroxynitrite effect).  CD4+ T cells 
cultured in 40nM and 10nM folate concentrations also increased KIR expression, 
as compared to RPMI 1640.  Simultaneous treatment with 20μM and 25μM 
peroxynitrite further increased expression of KIR (Figure 4.2B; p<0.001 for 
overall folate effect; p<0.05 for overall peroxynitrite effect).  No significant effects 
were observed in CD11a or perforin expression (data not shown). 
 
Peroxynitrite and methionine treatment.  CD4+ T cells cultured in 30µM and 
5µM methionine concentrations increased expression of CD70, as compared to 
the standard media, RPMI 1640.  Simultaneous treatment with 20μM and 25μM 
peroxynitrite further increased the expression of CD70 (Figure 4.2A; p<0.001 for 
overall methionine effect; p<0.001 for overall peroxynitrite effect).  CD4+ T cells 
cultured in 30μM and 5μM methionine concentrations also increased KIR 
expression, as compared to RPMI 1640.  Simultaneous treatment with 20μM and 
25μM peroxynitrite further increased expression of KIR (Figure 4.2B; p<0.001 for 
overall methionine effect; p<0.01 for overall peroxynitrite effect).  No significant 
effects were observed in CD11a or perforin expression (data not shown). 
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Discussion 
 The goal of this study was to examine how the combined effects of 
oxidative stress and altered nutrient status may affect expression of immune-
relevant methylation-sensitive genes.  The findings demonstrate an 
overexpression of methylation-sensitive genes when T cells are cultured in media 
with lower folate or methionine concentrations, and that ONOO- potentiates the 
effect.  Considering folate and methionine are key components of the 
transmethylation cycle, and ONOO- affects Dnmt through PKCδ, DNA 
methylation is a likely mechanism for the overexpression observed. 
Decreasing folate concentrations on untreated CD4+ T cells had a small 
effect on CD70 and KIR expression that increased significantly with ONOO- 
treatment.  The effect was more pronounced with KIR.  Similarly, decreasing 
methionine concentrations on untreated CD4+ T cells also had a small effect on 
CD70, a larger effect on KIR, and this was increased with ONOO- treatment.  The 
overexpression of CD70 and KIR was further increased when the cells were 
exposed to both lower nutrient and prooxidant conditions compared to just one of 
the conditions, suggesting that multiple „insults‟ may be additive.  Furthermore, 
the results support our hypothesis that T cells exposed to suboptimal nutrient 
conditions may be more sensitive to oxidative stress and vice versa. 
 We chose to examine gene expression of CD70 and KIR since it has 
previously been demonstrated that these genes are demethylated and 
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overexpressed in SLE.  CD70 is a B cell costimulatory molecule that is involved 
in antibody production.  The CD70 promoter (TNFSF7) is demethylated and 
CD70 is overexpressed in patients with active lupus .  CD4+ T cells treated with 
DNA methylation inhibitors and CD4+ lupus T cells also overstimulate B cell IgG 
production which is abrogated by anti-CD70 [51].  Importantly, CD70 expression 
was also increased in CD4+ T cells treated with Rottlerin, a selective PKCδ 
inhibitor [55].  KIR is normally expressed on NK cells but suppressed by DNA 
methylation on T cells [61].  Experimentally demethylated CD4+ T cells and T 
cells from lupus patients aberrantly express KIR, and in lupus patients, the 
expression correlates with disease activity.  Aberrant KIR expression may 
contribute to lupus by promoting macrophage killing and release of interferon-γ 
[62].  We also examined expression of CD11a and perforin but found no 
significant effect (data not shown). 
 Folate and methionine are highly relevant to the transmethylation cycle 
and therefore were the micronutrients chosen for this study.  Folate is known to 
modify DNA methylation patterns [110].  5-methyltetrahydrofolate (5-methylTHF), 
an intermediate in folate metabolism, provides the methyl donor to remethylate 
homocysteine to methionine [80, 81].  Hyperhomocysteinaemia in patients with 
chronic renal failure contributes to DNA demethylation, which can be reversed 
with folate supplementation [201].  Importantly, homocysteine levels are also 
elevated in lupus patients [79].  Since elevated homocysteine is a marker of 
possible folate deficiency [73], folate affects methylation, and T cells are 
hypomethylated in lupus, further investigation into the possible benefits of folate 
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supplementation in SLE may be indicated.  Methionine is an essential amino acid 
that maintains SAM levels [199].  Interestingly, reduced glutathione (GSH), a 
potent antioxidant, is depleted in SLE lymphocytes [185, 202], contributing to 
oxidative stress and DNA hypomethylation.  It has been hypothesized that 
methionine may be diverted from SAM synthesis in order to regenerate GSH [71], 
further highlighting the potential importance of dietary methionine in SLE. 
 Together, these studies suggest that an interruption in the methylation 
cycle from altered nutrient levels combined with decreased Dnmt1 enzymatic 
activity due to oxidative stress results in overexpression of CD70 and KIR. The 
results demonstrate that blockade of the methylation cycle via multiple 
mechanisms is additive.  Future studies such as those examining the levels of 
SAM and SAH will help determine the route by which altered micronutrients 
interrupt the methylation cycle.  Additional methylation studies of the CD70 and 
KIR promoter regions will help confirm the mechanism of action.  Further 
examination of other nutrient interactions with prooxidants will shed light on the 
complex interactions potentially contributing to autoimmunity. 
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Figure 4.1  Peroxynitrite and lower folate concentrations increase CD70 and 
KIR expression.  Culturing peroxynitrite-treated CD4+ T cells in media 
containing lower folate concentrations increases (A) CD70 (p<0.001 for overall 
folate effect; p<0.001 for overall peroxynitrite effect) and (B) KIR (p<0.001 for 
overall folate effect; p<0.05 for overall peroxynitrite effect) expression. n=6. 
  
 
 
 
 
 
 
 
 
  
 
 
 69 
 
 
 
 
 
Figure 4.2  Peroxynitrite and lower methionine concentrations increase 
CD70 and KIR expression.  Culturing peroxynitrite-treated CD4+ T cells in 
media containing lower methionine concentrations increases (A) CD70 (p<0.001 
for overall folate effect; p<0.001 for overall peroxynitrite effect; n=6) and (B) KIR 
(p<0.001 for overall folate effect; p<0.01 for overall peroxynitrite effect; n=5) 
expression.  
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APPENDIX A: DETERMINATION OF PEROXYNITRITE CONCENTRATIONS 
AND OXIDATIVE DAMAGE ENDPOINT 
 
Materials and Methods 
 To determine the optimal concentrations of peroxynitrite at which protein 
expression of methylation-sensitive genes is affected while likely causing 
oxidative damage, we performed several dose-response experiments to assess 
protein expression and used flow cytometry to assess cell integrity.  Blood was 
obtained from 4 different healthy donors.  PBMCs were isolated using Ficoll-
Hypaque Plus and stimulated with PHA for 24hours.  Cells were then washed 
and cultured in RPMI 1640 with 10% FBS at 37°C at 5% CO2 in a humidified 
environment, and treated with various concentrations of peroxynitrite (ONOO-) 
(ranging from 0-35μM) for 3 days.  After culture, cells were stained with 
antibodies for CD70, KIR, and perforin and analyzed by flow cytometry. 
 
Results 
Cell Integrity.  Forward and side scatter was observed for PBMCs, gating on the 
lymphocyte population (Figure A.1).  In the untreated (0μM ONOO-) sample, the 
majority of the cells can be seen in the gated lymphocyte (gate 1) population 
(Figure A.1.A).  In the 15μM, 20μM, and 25μM peroxynitrite concentrations, 
progressively fewer cells are seen in the gated lymphocyte population and more 
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cells can be seen shifted into the region of dead or dying cells (Figures A.1.B-
A.1.D).  At concentrations of 30μM and 35μM ONOO-, few cells remain in the 
gated lymphocyte population and most are present in the dead or dying 
population (Figures A.1.E and A.1.F).  Figure A.1 shows an overall progression 
of loss of cell integrity with increasing doses of ONOO-. 
 
Protein expression.  Cells were assessed for CD70, KIR, and perforin 
expression following peroxynitrite treatment to determine concentrations at which 
a change in expression occurs.  PBMCs from 3 healthy donors were treated with 
0μM, 2.5μM, 5μM, 10μM or 20μM ONOO- and then analyzed by flow cytometry 
for CD70, KIR and perforin expression (Figure A.2).  An increase in CD70, KIR 
and perforin expression was observed at concentrations of 10μM and 20μM 
ONOO-.  It was unclear whether higher than 20μM concentrations would have a 
similar increase, therefore cells from a 4th donor were used to assess protein 
expression at ONOO- concentrations of 0-30μM (Figure A.3).  Increasing protein 
expression of CD70 and KIR was observed at ONOO- concentrations of 15μM-
25μM. 
Summary 
These results confirm that 20μM and 25μM peroxynitrite are appropriate 
concentrations for our studies.  We chose these concentrations based on the 
forward and side scatter plots where there were still sufficient cells remaining in 
the lymphocyte population and at which there were observable effects on protein 
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expression.  Higher than 25μM concentrations (i.e.30μM) did show an increase in 
KIR expression on CD4+ T cells (Figure A.3), however this effect is likely only on 
very few cells as the scatter plots show very few cells remain in that population 
(Figure A.1E).  We did not directly measure oxidative damage in our studies, 
however it is likely that the concentrations used resulted in increased levels of 
oxidative stress since they are the highest concentrations at which cells were still 
viable and peroxynitrite is a known inducer of oxidative stress.  Furthermore, the 
concentrations used are well within the physiologic range, which has been 
estimated to be around 50μM [203] and reported to be as high as 500μM in 
phagolysosomes of activated macrophages [204].  
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Figure A.1:  Forward and Side Scatter of PBMCs treated with various 
concentrations of ONOO-.  Cells were treated with 0μM (A), 15μM (B), 20μM 
(C), 25μM (D), 30μM (E), or 35μM (F) ONOO- and forward and side scatter was 
observed by flow cytometry.  Cells are gated on the lymphocyte population (Gate 
1).  
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Figure A.2:  CD70, KIR, and perforin expression on CD4+ Tcells treated with 
0-20μM ONOO- from 3 donors.  
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Figure A.3: CD70 and KIR expression on CD4+ T cells treated with 0-30μM 
ONOO- from a 4th donor. 
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CHAPTER V: METHYLATION-SENSITIVE GENES ARE DIFFERENTIALLY 
EXPRESSED IN LUPUS VERSUS CONTROL CD4+ T CELLS EXPOSED TO 
ALTERED MICRONUTRIENTS 
 
Introduction 
 Systemic lupus erythematosus is an autoimmune disease characterized 
by CD4+ T cell demethylation.  DNA methylation is a postsynthetic modification 
where a methyl group is transferred to a cytosine nucleotide in the DNA.  The 
methylation reaction is mediated by the Dnmt group of enzymes and is also 
dependent on intracellular stores of the methyl donor SAM.  SAH, a by-product of 
methylation, inversely affects the methylation reaction by inhibiting Dnmt.  
Methylation of promoter regions of genes is typically associated with 
transcriptional suppression while demethylation results in gene expression. 
 In lupus, CD4+ T cells are demethylated at several promoter regions 
including CD11a, CD70, KIR, and perforin [184].  The demethylation causes 
overexpression of the genes, resulting in excess antibody production and 
macrophage killing.  Lupus patients have decreased Dnmt1 levels [170] that may 
be due in part to oxidative stress.  Dnmt1 is regulated by ERK pathway signaling.  
In lupus, defective PKCδ phosphorylation is at least in part responsible for 
defective ERK pathway signaling, resulting in failure to upregulate Dnmt1 [55].  
The defect has recently been attributed to the nitration of PKC δ [56]. 
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 Micronutrients from the diet also affect DNA methylation.  Methionine is 
necessary for the synthesis of SAM, the universal  methyl donor [67].  Methionine 
combines with ATP to produce SAM, therefore a decrease in methionine is likely 
to interrupt the methylation cycle.  Folate is an important component of the 
methylation cycle as well.  Folate serves as the methyl donor for homocysteine in 
the form of 5-methylTHF, to re-synthesize methionine.  A decrease in folate 
results in an accumulation of homocysteine, which participates in a reversible 
reaction strongly favoring SAH production.  Since SAH is an inhibitor of DNA 
methylation, a reduction in folate results in decreased DNA methylation. 
 Based on the knowledge that Dnmt1 levels are decreased in lupus 
patients and that micronutrients may alter DNA methylation, we hypothesized 
that lupus CD4+ T cells may be more sensitive to lower concentrations of 
methionine than cells from unaffected individuals.  We cultured CD4+ T cells 
from lupus patients and age- and gender-matched controls in media with varying 
amounts of methionine and examined protein expression of methylation-sensitive 
genes.  The results suggest that lupus patients may be less resistant to 
micronutrient deficiencies due to their already decreased levels of Dnmt1. 
 
Materials and  Methods 
Reagents.  RPMI 1640, RPMI1640 without folate and RPMI 1640 without 
methionine, and folate and methionine were all purchased from Invitrogen Life 
Technologies; Ficoll-Paque Plus was purchased from GE Healthcare; 
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phytohemagglutinin was purchased from Remel; and recombinant human IL-2 
was purchased from Peprotech.  Antibodies were purchased from BD 
Pharmingen, Beckman Coulter and R & D Systems.  Cytofix/Cytoperm Kit was 
purchased from BD Biosciences.  Standardization particles were purchased from 
Bangs Laboratories. 
 
Human subjects.   The University of Michigan Institutional Review Board for 
Human Subject Research reviewed and approved this study.  Patient samples 
were collected from the University of Michigan outpatient clinic with informed 
consent according to the Declaration of Helsinki.  Age- and gender-matched 
controls were recruited by advertising. 
 
Cell culture and treatment.  Human peripheral blood mononuclear cells 
(PBMCs) were isolated using Ficoll-Paque Plus density gradient centrifugation.  
Cells were cultured at 1x106/ml in RPMI 1640 with 10% fetal bovine serum (FBS), 
and 1µg/ml phytohemagglutinin, for 18-24hrs.  Cells were then washed and 
incubated with RPMI 1640 and either RPMI 1640 without folate or RPMI 1640 
without methionine, conventional or dialyzed FBS, and 10ng/ml recombinant 
human IL-2 for 3 days.  Cells were then harvested and washed for flow 
cytometric analysis. 
 
Flow cytometry.  Extracellular cell surface staining was performed using human 
antibodies for CD11a, CD70 and KIR.  Since the KIR molecules belong to a 
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family of polymorphic genes, a cocktail of KIR antibodies reactive to various KIR 
receptors was used: CD158b1/b2,j; CD158i; NKB1; CD158b; CD158a,h; 
KIR2DL4/CD158d.  Intracellular staining was performed using a human perforin 
antibody and the Cytofix/Cytoperm Kit.  Cells were stained and fixed, then 
analyzed on a FACSCalibur flow cytometer at least 24 hours later to allow for cell 
equilibration after contraction due to fixing.  Isotype and single-color positive 
controls were included in each condition.  Standardization particles for 
fluorescein isothiocyanate (FITC), phycoerythrin (PE) and cychrome (CYC) were 
run during each experiment for instrument calibration.  Ten thousand events in 
the gated lymphocyte population were captured.  Percent-positive cells were 
assessed for CD70, KIR and perforin.  Mean fluorescence intensity was 
assessed for CD11a and CD70.  Flow cyometric results were analyzed using 
FCS Express Software, version 3 (De Novo™ Software, Los Angeles, CA). 
  
Statistical analysis.  The gene expression in lupus patients was compared to 
age- and gender-matched controls at three different concentrations of methionine 
for each patient using a linear mixed model.  This model included a random 
effect for subject and a random effect for pair.  The fixed factors in the model 
were group (lupus or control), concentration (methionine 101μM, 30μM, and 
5μM), and their interaction.  Post-hoc tests were used to compare the lupus 
patients to normal controls at each level of methionine concentration, and to 
compare the methionine concentrations within a group (lupus or control).  
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Statistical analyses were conducted using IBM SPSS Statistics, version 21 for 
Windows, copyright IBM corporation 1989, 2012. 
 
Results 
Low methionine causes overexpression of CD70 in lupus CD4+ T cells.  To 
investigate whether lupus patients may be more sensitive to decreases in 
methionine, we cultured CD4+ T cells from patients and controls in various 
concentrations of methionine and examined CD70 protein expression.  PBMCs 
from 9 lupus patients and 9 age- and gender-matched controls were cultured in 
RPMI 1640 with 101μM, 30μM, or 5μM methionine for 4 days.  Cells were then 
stained with antibodies for CD4 and CD70 and analyzed by flow cytometry.  
Patients had a significant increase in CD70 expression (p=0.028 for overall 
methionine effect) compared to controls, when cultured in lower concentrations of 
methionine.  Patients had a significant increase between the highest and lowest 
methionine concentrations (p<0.026) (Figure 5.1). 
Low methionine causes overexpression of KIR in lupus CD4+ T cells.  To 
investigate whether lupus patients may be more sensitive to decreases in 
methionine, we cultured CD4+ T cells from patients and controls in various 
concentrations of methionine and examined KIR protein expression.  PBMCs 
from 9 lupus patients and 9 age- and gender-matched controls were cultured in 
RPMI 1640 with 101μM, 30μM, or 5μM methionine for 4 days.  Cells were then 
stained with antibodies for CD4 and KIR and analyzed by flow cytometry.  
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Patients and controls both had a significant increase in KIR expression (p=0.001 
and p=0.024 for overall methionine effect, respectively), when cultured in 
decreasing concentrations of methionine.  Patients and controls had a significant 
increase in KIR expression between 101μM and 5μM methionine concentrations 
(p=0.006; p=0.021, respectively).  Patients had a significant increase in KIR 
expression between 101μM and 30μM (p=0.003), but controls had no significant 
effect (Figure 5.2). 
Low methionine causes overexpression of perforin in lupus CD4+ T cells.  
To investigate whether lupus patients may be more sensitive to decreases in 
methionine, we cultured CD4+ T cells from patients and controls in various 
concentrations of methionine and examined perforin protein expression.  PBMCs 
from 9 lupus patients and 9 age- and gender-matched controls were cultured in 
RPMI 1640 with 101μM, 30μM, or 5μM methionine for 4 days.  Cells were then 
intracellularly stained with antibodies for CD4 and perforin and analyzed by flow 
cytometry.  Patients had a significant increase in perforin expression (p=0.008 for 
overall methionine effect), when cultured in decreasing concentrations of 
methionine. Controls had no significant effect.  Patients had a significant increase 
in expression when comparing methionine 101μM and 5μM (p=0.007).   (Figure 
5.3). 
Folate modifies expression of CD11a and CD70 in lupus T cells.  PBMCs 
from 11 lupus patients were cultured in RPMI 1640 with 2270nM, 40nM, or 10nM 
folic acid for 4 days.  Cells were then stained with antibodies for CD4 or CD8, 
and CD11a or CD70, and analyzed by flow cytometry.  Patients had a significant 
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increase in CD11a expression in both CD4+ and CD8+ T cells (p<0.001) when 
cultured in decreasing concentrations of folate (Figure 5.4).  Patients also had a 
significant increase in CD70 expression in both CD4+ and CD8+ T cells (p<0.001) 
when cultured in decreasing concentrations of folate (Figure 5.5). 
 
Discussion 
 Lupus patients have increased oxidative stress and decreased Dnmt1 
levels [170, 199].  We have shown in Chapter II of this dissertation that lupus 
patients have decreased serum methionine levels.  Since methionine is a 
necessary micronutrient in the methylation cycle, we examined whether lupus 
CD4+ T cells would be more sensitive to alterations in methionine levels due to 
their already low Dnmt1 levels in comparison to healthy controls. 
 We used 2 concentrations of methionine (30μM, 5μM) that are in the 
physiologic range, with one being at the high end and one in the lower end.  We 
also used standard RPMI 1640 for comparison, which contains 101μM 
methionine.  CD70 expression was unaffected in control CD4+ T cells in the 
lower concentrations of methionine.  Patient CD4+ T cells, however, had 
significant differential expression in the 3 concentrations of methionine (Figure 
5.1).  This supports our hypothesis that lupus patients are more sensitive to 
transmethylation micronutrient alterations.  We also assessed KIR expression.  In 
the controls, there was a significant increase in KIR expression in the lowest 
methionine concentration, resulting in an overall methioinine effect, however 
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there was no difference in expression in the 2 higher concentrations.  The 
patients also had a significant overall effect of methionine concentration and 
interestingly did have a significant increase in expression between the 2 higher 
concentrations (101μM and 30μM) (Figure 5.2).  Considering 30μM is considered 
„high physiologic‟ concentration, this suggests that in lupus patients, higher than 
30μM concentrations of methionine may be needed to prevent increasing KIR 
expression.  Finally, we examined perforin expression in the presence of the 3 
methioinine concentrations.  The controls once again had no significant increase 
in perforin expression across the concentrations of methionine, however the 
patients had a significant increase overall, and in the lowest concentration 
compared to standard RPMI 1640 (Figure 5.3).  Together, these results suggest 
that lupus CD4+ T cells are more susceptible to overexpressing CD70, KIR, and 
perforin when exposed to a low methionine environment. 
 Additionally, we examined the effects of altered folate levels on T cell 
gene expression in lupus T cells.  We used 2 concentrations of folic acid, 40nM 
and 10nM, which are considered to be the higher and lower physiologic levels.  
Standard RPMI 1640, which contains 2270nM folic acid, was used as a control. 
Expression of CD11a and CD70 both significantly increased when cultured in 
decreasing levels of folate, in both CD4+ and CD8+ T cells.  We do not have 
data comparing this to control CD4+ T cells at this time, however considering 
folate is decreased in some lupus patients [79], and that in Chapter IV of this 
dissertation we show a synergistic effect of lower folate concentrations and 
oxidants on methylation-sensitive gene expression, we hypothesize that the 
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lupus CD4+ T cells will be more sensitive to lower folate concentrations 
compared to controls as well.  Studies are ongoing to investigate this.    
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Figure 5.1  Low methionine causes overexpression of CD70 in lupus 
CD4+ T cells.  PBMCs from 9 lupus patients and 9 age- and gender-
matched controls were cultured in RPMI 1640 with 101μM, 30μM or 5μM 
methionine as described in “Materials and Methods” section.  Cells were 
than stained with antibodies for CD4 or CD70 and analyzed by flow 
cytometry.  There was a significant overall methionine effect (p=0.028) in 
patients but not controls. 
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Figure 5.2  Low methionine causes overexpression of KIR in 
lupus CD4+ T cells.  PBMCs from 9 lupus patients and 9 age- and 
gender- matched controls were cultured in RPMI 1640 with 101μM, 
30μM, or 5μM methionine as described in “ Materials and Methods” 
section.  Cells were than stained with antibodies for CD4 or KIR and 
analyzed by flow cytometry.  There was a significant overall 
methionine effect in controls (p=0.024) and in patients (p=0.001). 
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Figure 5.3  Low methionine causes overexpression of perforin in 
lupus CD4+ T cells.  PBMCs from 9 lupus patients and 9 age- and 
gender-matched controls were cultured in RPMI 1640 with 101μM, 
30μM, or 5μM methionine as described in “Materials and Methods” 
section.  Cells were then stained with antibodies for CD4 or perforin and 
analyzed by flow cytometry.  There was a significant overall methionine 
effect in patients (p=0.008) but not in controls. 
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Figure 5.4  Folate modifies expression of CD11a in lupus CD4+ 
T cells.  PBMCs from 11 lupus patients were cultured in RPMI 1640 
with 2270nM, 40nM, or 10nM folic acid as described in “Materials 
and Methods” section.  Cells were then stained with antibodies for 
CD4 or CD8, and CD11a and analyzed by flow cytometry.  The 
effect of folate on CD11a expression was significant in both CD4+ 
(p<0.001) and CD8+ (p<0.001) T cells. 
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Figure 5.5  Folate modifies expression of CD70 in lupus T cells.  
PBMCs from 11 lupus patients were cultured in RPMI 1640 with 
2270nM, 40nM, or 10nM folic acid as described in “Materials and 
Methods” section.  Cells were then stained with antibodies for CD4 
or CD8, and CD70.  The effect of folate on CD11a expression was 
significant in both CD4+ (p<0.001) and CD8+ (p<0.001) T cells. 
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CHAPTER VI: CONCLUSION 
 
Introduction  
T cell DNA demethylation is associated with autoimmunity in SLE.  The 
mechanisms linking environmental factors and dysregulation of methylation in the 
disease, however still remain unclear.  Through the research presented in this 
dissertation, we have demonstrated that transmethylation micronutrient 
alterations affect methylation-sensitive gene expression in T cells in lupus.  We 
have shown that lupus patients have serum/plasma levels of transmethylation 
micronutrients that differ from the normal population.  In vitro, transmethylation 
mmicronutrient levels in tissue culture media modulate expression of 
methylation-sensitive genes in T cells.  Furthermore, we demonstrate the 
synergistic effects of oxidative stress and micronutrient alterations in promoting 
increased protein expression of methylation-sensitive genes in T cells.  CD4+ T 
cells from lupus patients display an increased sensitivity to altered methionine 
levels by aberrantly expressing methylation-sensitive genes compared to CD4+ T 
cells from healthy controls.  This is likely due to the decreased Dnmt1 levels and 
increased oxidative stress in lupus.  To our knowledge, this is the first report 
demonstrating a relationship between oxidative stress and micronutrient effects 
on T cell methylation-sensitive gene expression relating to SLE. 
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 Further work is needed to establish the mechanisms involved.  Currently, 
methylation studies are underway to confirm the methylation changes that are 
likely occurring.  Additional studies including the measurement of SAM/SAH 
ratios would help to establish a mechanism by which altered micronutrients are 
exerting their effects.  Several factors may be involved. The metabolism of 
micronutrients in addition to quantities available are likely to be a factor.  A 
polymorphism of the methionine synthase enzyme involved in folate and 
methionine metabolism has been associated with increased risk of SLE [90].  
Furthermore, a recent study has shown several genes  involved in the folate 
biosynthesis pathway to be hypermethylated in lupus CD4+ T cells compared to 
normal controls [205].  Studies in which these changes can be correlated with 
micronutrient effects in vitro may shed light on mechanisms by which altered 
micronutrients may be differentially affecting lupus patients.  Oxidants such as 
peroxynitrite may be affecting Dnmt1 enzymatic activity through nitration of 
tyrosine residues of PKCδ [56] as discussed earlier in this dissertation, thus 
having a concurrent effect on methylation.  Peroxynitrite can also react with 
methionine and inactivate methioinine-containing proteins by oxidizing 
methionine residues [206].  This may represent another mechanism by which 
altered micronutrients and oxidative stress interact to cause altered methylation-
sensitive gene expression, and merits further study.   
 This work is significant because the overexpression of CD4+ T cell 
methylation-sensitive genes in lupus has functional consequences, including 
increased antibody production and macrophage killing [51, 62].  These effects 
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contribute to disease pathogenesis and subsequent morbidity (Figure 6.1).  By 
demonstrating that transmethylation micronutrients alter methylation-sensitive 
gene expression in lupus, this work identifies a potentially modifiable mechanism 
which may have therapeutic applications. 
 
Public Health Implications 
 The burden of autoimmune disease worldwide is significant.  In the United 
States, it is estimated that 5-8% of the population has at least one autoimmune 
disease, which corresponds to between 15 and 24 million people [207].  The 
majority of autoimmune diseases disproportionately affect women for reasons 
that are still unclear.  Furthermore, all autoimmune diseases have a genetic and 
environmental component that combine to cause pathogenesis. 
 SLE is one of many autoimmune diseases, however it is a prototypic 
autoimmune disease to study.  The features of SLE are common to many other 
autoimmune diseases, and findings from lupus research can be extended to 
some of the other diseases.  During the past 50 years, only one new drug has 
been developed and FDA approved for the treatment of lupus.  The drug, 
Benlysta, is a human monoclonal antibody that targets B-lymphocyte stimulator, 
thereby reducing autoantibody production.  However, there are significant costs 
and side effects associated with this new drug.  Side effects include infections, 
cancers, depression, and suicide.  Moreover, the drug is modestly effective, 
offering benefit to about 30% of patients, and not those with the most severe 
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disease involving organ damage [208].  This highlights the need for further 
research into novel treatments for SLE and other autoimmune diseases. 
 SLE has a genetic component, evidenced by the monogenic forms of the 
disease, though generally lupus is a polygenic disease.  Lupus also has an 
environmental component, and this is best seen in cases of drug-induced lupus 
where certain drugs directly cause lupus and the disease remits when the inciting 
agent is removed [17].  Age may also play a role in disease development since 
the incidence of lupus increases with age [209], and this may be due to an 
accumulation of environmental „insults‟ over time.  These components make SLE 
a model autoimmune disease in which to study environmental effects.  Several 
environmental agents in addition to drugs have been associated with SLE, 
including silica dust [14], cigarette smoking [15], and infectious agents [16].  
Oxidative stress is a common mechanism to these three environmental triggers 
and may be occurring with others.  We explored the role of dietary micronutrients 
as a possible environmental factor in affecting lupus as well as oxidative stress.  
In Chapter II of this dissertation, we show decreased levels of zinc, vitamin B6, 
and methionine and increased levels of homocysteine in lupus patients 
compared to the normal population.  In Chapter IV, we establish a relationship 
between oxidative stress and micronutrient level effects on T cell methylation-
sensitive gene expression, and show that lupus CD4+ T cells are more sensitive 
to micronutrient alterations in Chapter V.  Given the fact that dietary 
micronutrients are relatively easily modified, these results warrant further 
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investigation into the role of micronutrients as a potential benefit for therapy 
and/or prevention. 
 
Summary 
In summary, through the research presented in this thesis, we have 
demonstrated a role for micronutrients in modulating T cell methylation-sensitive 
gene expression in lupus.  We have shown a decrease in zinc, vitamin B6, and 
methionine, and an increase in homocysteine in the serum of lupus patients.  
Alterations in micronutrient levels modulate T cell methylation-sensitive gene 
expression in vitro.  Furthermore, oxidative stress and altered micronutrient 
levels are additive in affecting immune-relevant methylation-sensitive gene 
expression in T cells.  Given that lupus patients have decreased Dnmt1 levels 
likely resulting from oxidative stress, and we show that CD4+ T cells from lupus 
patients are more sensitive to decreases in methionine, dietary modification may 
have therapeutic implications in SLE and potentially other autoimmune diseases.  
Further studies are needed to elucidate the complex interactions of 
transmethylation micronutrients, oxidative stress, and DNA methylation in lupus.  
The work presented in this dissertation will hopefully serve as a basis for future 
investigation into potential therapies in the field of autoimmunity. 
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Figure 6.1: Model 
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